Hand Composite Employee Benefit Trust QS U.S. Small Capitalization Equity CIF

Independent Auditor's Report and Financial Statements December 31, 2019



Hand Composite Employee Benefit Trust December 31, 2019

Contents

Independent Auditor's Report	1
Basic Financial Statements	
Statement of Assets and Liabilities - Selected Fund	
Schedule of Investments	
QS U.S. Small Capitalization Equity CIF	4
Statement of Operations - Selected Fund	16
Statement of Changes in Net Assets - Selected Fund	
Notes to Financial Statements	

Supplemental Information

Schedule of Investment Purchases and Sales - Selected Fund	2	:4
--	---	----



Independent Auditor's Report

Board of Directors Hand Composite Employee Benefit Trust Houston, Texas

We have audited the accompanying financial statements of the selected fund, QS U.S. Small Capitalization Equity CIF, included in the Hand Composite Employee Benefit Trust ("Trust" or "Fund"), which comprise the statement of assets and liabilities, including the schedule of investments, as of December 31, 2019, and the related statements of operation and changes in net assets for the year then ended and the related notes to the financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.



Board of Directors Hand Composite Employee Benefit Trust Page 2

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the selected fund, QS U.S. Small Capitalization Equity CIF, as of December 31, 2019, the results of its operations and the changes in its net assets for the year then ended, in accordance with accounting principles generally accepted in the United States of America.

Supplementary Information

Our audit was conducted for the purpose of forming an opinion on the financial statements as a whole. The schedule of investment purchases and sales listed in the table of contents is presented for purposes of additional analysis and is not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated in all material respects in relation to the financial statements as a whole.

BKD,LIP

Houston, Texas May 22, 2020

Statement of Assets and Liabilities – Selected Fund December 31, 2019

	QS U.S. Small Capitalization Equity CIF	
Assets		<u> </u>
Investments, at cost	\$	750,248,825
Investments, at fair value	\$	773,209,301
Cash		73,710
Receivable for:		
Capital shares sold		839,032
Dividends and interest		883,518
Investment advisor waived fees		8
Total assets	\$	775,005,569
Liabilities		
Payable for capital shares redeemed	\$	824,216
Management fee payable		273,050
Accounts payable and accrued liabilities		57,000
Total liabilities	\$	1,154,266
Net assets held for participants:		
Class R4	\$	773,504,053
Class R-INT		347,250
Total net assets held for participants	\$	773,851,303
Units outstanding:		
Class R4		73,940,590
Class R-INT		33,079
Total units outstanding		73,973,669
Net asset value per unit:		
Class R4	\$	10.46
Class R-INT	\$	10.50

Schedule of Investments QS U.S. Small Capitalization Equity CIF December 31, 2019

Number of Shares			Cost	F	air Value
	Short Term Investment				
2,014,690	State Street Institutional Investment Trust Treasury Money				
2,014,090	Market Fund, Premier Class 1.52%	\$	2,014,690	\$	2,014,690
	Total Short Term Investment	0.26%	2,014,690		2,014,690
	<u>Common Stocks</u>				
	Consumer Discretionary				
20,400	America's Car-Mart, Inc.		1,813,368		2,237,064
65,254	BJ's Restaurants, Inc.		2,033,632		2,477,042
170,000	Bloomin' Brands, Inc.		3,124,203		3,751,900
131,000	Boyd Gaming Corp.		3,357,498		3,922,140
62,000	Brinker International, Inc.		2,882,038		2,604,000
45,400	Cheesecake Factory, Inc.		1,727,111		1,764,244
115,499	Crocs, Inc.		2,365,917		4,838,25
310,100	Dana, Inc.		6,893,170		5,643,82
29,341	Deckers Outdoor Corp.		2,034,021		4,954,52
55,900	Dick's Sporting Goods, Inc.		1,883,927		2,766,49
42,000	Dine Brands Global, Inc.		3,560,800		3,507,84
95,000	Ethan Allen Interiors, Inc.		1,823,998		1,810,70
35,000	Frontdoor, Inc.		1,468,950		1,659,70
91,064	Genesco, Inc.		2,424,432		4,363,78
123,645	Hibbett Sports, Inc.		1,746,408		3,467,00
29,700	Jack in the Box, Inc.		2,743,806		2,317,49
75,000	K12, Inc.		2,532,384		1,526,25
117,785	KB Home		2,811,468		4,036,492
13,200	Lithia Motors, Inc. Class A		1,810,351		1,940,40
84,545	MDC Holdings, Inc.		2,417,262		3,226,23
37,000	Meritage Homes Corp.		1,699,462		2,261,070
50,000	Penn National Gaming, Inc.		1,154,457		1,278,000
82,000	Rent-A-Center, Inc.		2,117,883		2,364,880
76,100	SeaWorld Entertainment, Inc.		2,244,303		2,413,13
24,000	Shoe Carnival, Inc.		803,854		894,720
42,000	Signet Jewelers Ltd.		1,985,131		913,08
95,416	Sinclair Broadcast Group, Inc. Class A		2,910,112		3,181,170
35,000	Sleep Number Corp.		1,676,386		1,723,400

umber of Shares			Cost	Fair Value
	Consumer Discretionary (Continued)			
142,700	Sonos, Inc.	S	\$ 1,916,858	\$ 2,228,97
67,000	Tenneco, Inc. Class A		3,841,770	877,70
18,800	Universal Electronics, Inc.		941,374	982,48
48,000	Winnebago Industries, Inc.		2,285,615	2,543,04
90,000	WW International, Inc.		4,239,555	3,438,90
	Total Consumer Discretionary	11.37%	79,271,504	87,915,93
	Consumer Staples			
88,000	Andersons, Inc.		1,911,961	2,224,64
8,300	Boston Beer Co., Inc. Class A		2,269,014	3,136,15
12,200	John B Sanfilippo & Son, Inc.		1,187,909	1,113,61
35,000	Sanderson Farms, Inc.		5,407,569	6,167,70
154,923	SpartanNash Co.		2,395,764	2,206,10
28,100	Spectrum Brands Holdings, Inc.		1,587,029	1,806,54
75,000	United Natural Foods, Inc.		1,772,078	657,00
20,000	USANA Health Sciences, Inc.		2,178,640	1,571,00
	Total Consumer Staples	2.44%	18,709,964	18,882,76
	Energy			
34,000	Arch Coal, Inc. Class A		3,046,281	2,439,16
110,000	Delek US Holdings, Inc.		2,972,666	3,688,30
315,900	DHT Holdings, Inc.		1,788,836	2,615,65
72,600	GasLog Ltd.		1,066,655	710,75
38,400	International Seaways, Inc.		1,067,793	1,142,78
500,000	Nordic American Tankers Ltd.		1,122,861	2,460,00
89,100	PDC Energy, Inc.		2,482,289	2,331,74
25,463	REX American Resources Corp.		2,140,965	2,086,94
102,000	SM Energy Co.		2,208,042	1,146,48
498,600	Southwestern Energy Co.		2,111,809	1,206,61
65,000	Talos Energy, Inc.		1,657,327	1,959,75
124,000	World Fuel Services Corp.		3,528,166	5,384,08
	Total Energy	3.51%	25,193,690	27,172,26

hares		Cost	 Fair Value
	Financials		
36,800	Affiliated Managers Group, Inc.	\$ 3,208,557	\$ 3,118,43
4,500	Alexander's, Inc. REIT	1,466,892	1,486,57
97,141	American Equity Investment Life Holding Co.	2,812,355	2,907,43
74,504	Artisan Partners Asset Management, Inc. Class A	1,986,960	2,407,96
38,000	Assured Guaranty Ltd.	1,581,647	1,862,76
100,000	Axos Financial, Inc.	2,732,741	3,028,00
176,300	Bancorp, Inc.	1,615,952	2,286,61
78,000	Bank of NT Butterfield & Son Ltd.	2,977,977	2,887,56
42,100	Banner Corp.	2,293,345	2,382,43
69,429	Berkshire Hills Bancorp, Inc.	2,505,204	2,282,82
263,500	Boston Private Financial Holdings, Inc.	3,036,722	3,169,90
220,000	Brightsphere Investment Group, Inc.	3,102,267	2,248,40
20,000	Byline Bancorp, Inc.	365,959	391,40
180,000	Cadence BanCorp	3,987,548	3,263,40
109,000	CareTrust REIT, Inc. REIT	2,251,875	2,248,67
19,509	Community Trust Bancorp, Inc.	875,331	909,90
225,000	CoreCivic, Inc. REIT	4,512,977	3,910,50
55,400	Cowen, Inc.	826,033	872,55
85,267	Customers Bancorp, Inc.	2,528,955	2,030,20
56,600	Encore Capital Group, Inc.	2,003,573	2,001,37
191,762	Enova International, Inc.	3,501,761	4,613,79
135,539	Essent Group Ltd.	5,229,369	7,046,67
40,471	Evercore, Inc. Class A	3,179,342	3,025,61
312,906	EZCORP, Inc. Class A	2,879,201	2,134,01
78,000	Federated Investors, Inc. Class B	1,933,495	2,542,02
259,000	FGL Holdings	2,138,197	2,758,35
370,684	First Bancorp	1,906,130	3,925,54
50,000	First Busey Corp.	1,299,656	1,375,00
121,601	First Commonwealth Financial Corp.	1,722,342	1,764,43
41,600	First Financial Corp.	1,783,447	1,901,95
134,114	First Midwest Bancorp, Inc.	3,103,860	3,092,66
104,000	Flagstar Bancorp, Inc.	3,343,823	3,978,00
	Global Medical REIT, Inc.	1,679,559	1,984,50
<i>,</i>	Hancock Holding Co.	3,291,777	3,159,36
	Hanmi Financial Corp.	4,043,836	2,713,68

Number of Shares			Cost	Fair Value
				74140
	Financials (Continued)			
49,300	HCI Group, Inc.	S	\$ 2,267,320	\$ 2,250,545
46,000	Health Insurance Innovations, Inc. Class A		1,340,076	887,340
47,823	Heartland Financial USA, Inc.		2,238,725	2,378,716
108,550	Hilltop Holdings, Inc.		2,790,114	2,706,151
137,000	Hope Bancorp, Inc.		2,280,596	2,035,820
65,344	IBERIABANK Corp.		5,375,433	4,889,691
108,000	Industrial Logistics Properties Trust REIT		2,186,773	2,421,360
12,341	Jones Lang LaSalle, Inc.		1,752,237	2,148,445
280,000	MGIC Investment Corp.		3,408,657	3,967,600
64,700	Midland States Bancorp, Inc.		1,692,205	1,873,712
155,000	Monmouth Real Estate Investment Corp. REIT		2,039,771	2,244,400
173,800	Mr Cooper Group, Inc.		1,816,023	2,174,238
65,000	National General Holdings Corp.		1,572,188	1,436,500
168,600	Newmark Group, Inc. Class A		2,261,780	2,268,513
142,000	OFG Bancorp		1,766,108	3,352,620
50,868	Park Hotels & Resorts, Inc. REIT		1,317,990	1,315,955
46,243	PennyMac Financial Services, Inc.		828,689	1,574,112
43,000	Peoples Bancorp, Inc.		1,414,080	1,490,380
15,929	Primerica, Inc.		1,252,328	2,079,690
196,169	Radian Group, Inc.		3,627,071	4,935,612
13,000	Regional Management Corp.		350,299	390,390
12,000	Safety Insurance Group, Inc.		1,161,480	1,110,360
62,000	Sandy Spring Bancorp, Inc.		2,278,102	2,348,560
101,700	Simmons First National Corp. Class A		2,402,728	2,724,543
55,000	Stifel Financial Corp.		2,886,659	3,335,750
99,300	Umpqua Holdings Corp.		1,627,874	1,757,610
96,537	Universal Insurance Holdings, Inc.		2,324,441	2,702,071
50,000	Wintrust Financial Corp.		3,818,951	3,545,000
	Total Financials	20.44%	147,787,363	158,058,198
	Healthcare			
48,000	ACADIA Pharmaceuticals, Inc.		712,560	2,053,440
336,218	Achillion Pharmaceuticals, Inc.		1,604,586	2,027,394
76,725	Acorda Therapeutics, Inc.		2,057,194	156,519

Shares Cost Fair Value J13.500 Akorn, Inc. \$ 1.464.376 \$ 4.70.250 5.500 Allakos, Inc. 6.86.321 524.480 7.4052 MAG Pharmaceuticals, Inc. 1.450.712 901.213 22,000 Amedisys, Inc. 2.646.116 3.672.240 100.742 Anicus Therapeutics, Inc. 1.456.193 981.227 5.5037 Amplaster Pharmaceuticals, Inc. 1.018.915 1.061.664 2.8000 ANI Pharmaceuticals, Inc. 1.734.827 2.379.610 174.900 Apyx Medical Corp. 1.229.550 1.479.654 48.444 Arena Pharmaceuticals, Inc. 1.334.061 4.650.309 73.000 Arrowshead Pharmaceuticals, Inc. 1.314.061 4.650.309 29.000 Bioprim Medicines Corp. 2.174.620 2.323.190 29.000 Bioprim Medicines Corp. 1.852.532 3.157.913 51.000 Carabys, Inc. 1.854.847 1.344.440 1.900 Steprim Medicines, Inc. 1.854.650 1.91.38 Celldex Therapeutics,	Number of			
313,500 Akorn, Inc. \$ 1,464,376 \$ 470,250 5,500 Allakos, Inc. 666,321 524,480 74,052 AMAG Pharmaceuticals, Inc. 1,450,712 901,213 22,000 Amedisys, Inc. 1,456,116 3,672,240 100,742 Amicus Therapeutics, Inc. 1,456,113 981,227 55,037 Amphastar Pharmaceuticals, Inc. 1,018,915 1,061,664 28,000 ANP Pharmaceuticals, Inc. 1,734,827 2,379,610 50,6300 Antares Pharma, Inc. 1,239,550 1,479,654 48,444 Arene Pharmaceuticals, Inc. 2,224,778 2,200,326 73,000 Arrowhead Pharmaceuticals, Inc. 191,146 366,864 15,000 Biohaven Pharmaceutical, Inc. 191,146 366,864 15,000 Cardiovascular Systems, Inc. 1,354,440 1,100,070 357,600 Cardiovascular Systems, Inc. 1,354,440 1,000,70 357,600 Cardiovascular Systems, Inc. 1,354,440 1,000,70 357,600 Cardiovascular Systems, Inc. 1,354,440 1,000,70 357,600 Cardiovascular Systems, Inc.	Shares		Cost	Fair Value
5,500 Allakos, Inc. 686,321 524,480 74,052 AMAG Pharmaceuticals, Inc. 1,450,712 901,213 22,000 Amedisys, Inc. 2,646,116 3,672,240 100,742 Amicus Therapeutics, Inc. 1,456,193 981,227 55,037 Amphastar Pharmaceuticals, Inc. 1,018,915 1,061,664 28,000 ANI Pharmaceuticals, Inc. 1,630,247 1,726,760 506,300 Antress Pharma, Inc. 1,239,950 1,479,654 714,900 Apys Medical Corp. 1,229,550 1,479,654 48,444 Arena Pharmaceuticals, Inc. 2,224,778 2,200,326 73,000 Arowhead Pharmaceutical Holding Co., Ltd. 657,508 816,600 15,000 Biohaven Pharmaceutical Holding Co., Ltd. 657,508 816,600 29,000 Blueprint Medicines Corp. 2,174,620 2,323,190 64,991 Cardoxacular Systems, Inc. 1,853,437 1,310,070 375,000 Cardoxacular Systems, Inc. 1,867,035 1,549,450 19,138 Celldex Therapeutics, Inc. 1,863,457 1,341,000 95,000 Catasys, Inc. <th></th> <th>Healthcare (Continued)</th> <th></th> <th></th>		Healthcare (Continued)		
74.052 AMAG Pharmaceuticals, Inc. 1.450,712 901,213 22.000 Amedisys, Inc. 2.646,116 3.672,240 100,742 Amicus Therapeutics, Inc. 1.018,915 1.061,664 28,000 ANI Pharmaceuticals, Inc. 1.018,915 1.061,664 28,000 ANI Pharmaceuticals, Inc. 1.630,247 1.726,760 506,300 Antares Pharma, Inc. 1.734,827 2.379,610 174,900 Apys Medical Corp. 1.229,550 1.479,654 48,444 Arena Pharmaceuticals, Inc. 2.224,778 2.200,326 73,000 Arrowhead Pharmaceuticals, Inc. 1.334,061 4.630,390 47,831 Avid Bioservices, Inc. 1.91,146 366,864 15,000 Biophave Pharmaceutical Holding Co., Ltd. 657,508 816,600 29,000 Biuperint Medicines Corp. 2.174,4620 2.323,190 64,991 Cardiovascular Systems, Inc. 1.854,3457 1.341,000 95,000 Catasys, Inc. 1.863,457 1.341,000 95,000 Contasys, Inc. 1.863,139 42,678 148,940 Chimerix, Inc. 1.91,5692<	313,500	Akorn, Inc.	\$ 1,464,376	\$ 470,250
22,000 Amedisys, Inc. 2,646,116 3,672,240 100,742 Amicus Therapeutics, Inc. 1,456,193 981,227 55,037 Amphastar Pharmaceuticals, Inc. 1,018,915 1,016,64 28,000 ANI Pharmaceuticals, Inc. 1,630,247 1,726,760 506,300 Antares Pharma, Inc. 1,734,827 2,379,610 174,900 Apyx Medical Corp. 1,229,550 1,479,654 48,444 Arena Pharmaceuticals, Inc. 2,224,778 2,200,326 73,000 Arrowhead Pharmaceuticals, Inc. 1,334,061 4630,390 47,831 Avid Bioservices, Inc. 191,146 366,864 15,000 Biueprint Medicines Corp. 2,174,620 2,323,190 24,991 Cardiovascular Systems, Inc. 1,852,532 3,157,913 51,000 CareDx, Inc. 1,863,457 1,341,000 95,000 Catalyst Pharmaceuticals, Inc. 1,863,457 1,341,000 95,000 Catalyst, Inc. 1,863,139 42,678 148,940 Chimerix, Inc. 1,915,692 1,429,875 325,000 Concoret Pharmaceuticals, Inc. 1,915,692 <td>5,500</td> <td>Allakos, Inc.</td> <td>686,321</td> <td>524,480</td>	5,500	Allakos, Inc.	686,321	524,480
100,742 Amicu Therapeutics, Inc. 1,456,193 981,227 55,037 Amphastar Pharmaceuticals, Inc. 1,018,915 1,061,664 28,000 ANT Pharmaceuticals, Inc. 1,630,247 1,726,760 506,300 Antares Pharma, Inc. 1,734,827 2,379,610 174,900 Apyx Medical Corp. 1,229,550 1,479,654 48,444 Arena Pharmaceuticals, Inc. 2,224,778 2,200,326 73,000 Arowhead Pharmaceuticals, Inc. 1,334,061 4,630,390 47,813 Avid Bioservices, Inc. 191,146 366,864 15,000 Biueprint Medicines Corp. 2,174,620 2,323,190 64,991 Cardiovascular Systems, Inc. 1,852,532 3,157,913 51,000 Caraby, Inc. 1,863,457 1,341,000 95,000 Catabyst Pharmaceuticals, Inc. 1,863,457 1,341,000 95,000 Catabyst Pharmaceuticals, Inc. 1,915,692 1,429,875 125,700 Conformis, Inc. 1,915,692 1,429,875 125,700 Contert Pharmaceuticals, Inc. 1,915,692 1,429,875 125,700 Conterr Pharmaceutical	74,052	AMAG Pharmaceuticals, Inc.	1,450,712	901,213
55.037 Amphastar Pharmaceuticals, Inc. 1.018,915 1.061,664 28,000 ANI Pharmaceuticals, Inc. 1.630,247 1.726,760 506,300 Antares Pharma, Inc. 1.734,827 2.379,610 174,900 Apyx Medical Corp. 1.229,550 1.479,654 48,844 Arena Pharmaceuticals, Inc. 2.224,778 2.200,326 73,000 Arrowhead Pharmaceuticals, Inc. 1.334,061 4.630,390 47,831 Avid Bioservices, Inc. 191,146 366,864 15,000 Biohaven Pharmaceutical Holding Co., Ltd. 657,508 816,600 29,000 Biueprint Medicines Corp. 2,174,620 2.323,190 64,991 Cardiovascular Systems, Inc. 1.852,532 3,157,913 51,000 Catalyst Pharmaceuticals, Inc. 1.867,035 1,549,450 19,138 Celldex Therapeutics, Inc. 1.867,035 1,429,450 148,940 Chimerix, Inc. 800,336 302,348 155,000 Concert Pharmaceuticals, Inc. 1.918,618 487,500 129,708 Corcept Therapeutics, Inc.	22,000	Amedisys, Inc.	2,646,116	3,672,240
28,000 ANI Pharmaceuticals, Inc. 1,630,247 1,726,760 506,300 Antares Pharma, Inc. 1,734,827 2,379,610 174,900 Apyx Medical Corp. 1,229,550 1,479,654 48,444 Arena Pharmaceuticals, Inc. 2,224,778 2,200,326 73,000 Arowhed Pharmaceuticals, Inc. 1,334,061 4,630,390 47,831 Avid Bioservices, Inc. 191,146 366,864 15,000 Bioparen Pharmaceutical Holding Co., Ltd. 657,508 816,600 29,000 Blueprint Medicines Corp. 2,174,620 2,323,190 64,991 Cardiovascular Systems, Inc. 1,854,347 1,341,000 95,000 CareDx, Inc. 1,863,457 1,341,000 95,000 Catalyst Pharmaceuticals, Inc. 1,863,3139 42,678 148,940 Chimerix, Inc. 800,336 302,348 155,000 Concert Pharmaceuticals, Inc. 1,138,618 487,500 129,708 Corcept Therapeutics, Inc. 1,138,618 487,500 129,700 Editas Medicine, Inc. 1,138,618 487,500 129,700 Editas Medicine, Inc. <	100,742	Amicus Therapeutics, Inc.	1,456,193	981,227
506,300 Antares Pharma, Inc. 1,734,827 2,379,610 174,900 Apyx Medical Corp. 1,229,550 1,479,654 48,444 Arena Pharmaceuticals, Inc. 2,224,778 2,200,326 73,000 Arrowhead Pharmaceuticals, Inc. 1,334,061 4,630,390 47,831 Avid Bioservices, Inc. 191,146 366,864 15,000 Biohaven Pharmaceutical Holding Co., Ltd. 657,508 816,600 29,000 Blueprint Medicines Corp. 2,174,620 2,323,190 64,991 Cardiovascular Systems, Inc. 1,354,440 1,100,070 357,600 Catalyst Pharmaceuticals, Inc. 1,863,457 1,341,000 95,000 Catasys, Inc. 1,867,035 1,549,450 19,138 Celldex Therapeutics, Inc. 863,139 42,678 148,940 Chimerix, Inc. 800,336 302,348 155,000 Concert Pharmaceuticals, Inc. 1,915,692 1,429,875 325,000 Conformis, Inc. 1,138,618 487,500 129,708 Corcept Therapeutics, Inc. 1,612,555	55,037	Amphastar Pharmaceuticals, Inc.	1,018,915	1,061,664
174,900 Apyx Medical Corp. 1,229,550 1,479,654 48,444 Arena Pharmaceuticals, Inc. 2,224,778 2,200,326 73,000 Arrowhead Pharmaceuticals, Inc. 1,334,061 4,630,390 47,831 Avid Bioservices, Inc. 1,91,146 366,864 15,000 Biohaven Pharmaceutical Holding Co., Ltd. 657,508 816,600 29,000 Blueprint Medicines Corp. 2,174,620 2,323,190 64,991 Cardiovascular Systems, Inc. 1,354,440 1,100,070 357,600 Catalyst Pharmaceuticals, Inc. 1,863,457 1,341,000 95,000 Catasys, Inc. 1,867,035 1,549,450 19,138 Celldex Therapeutics, Inc. 863,139 42,678 148,940 Chimerix, Inc. 800,336 302,348 155,000 Concert Pharmaceuticals, Inc. 1,915,692 1,429,875 325,000 Conformis, Inc. 1,138,618 487,500 129,708 Corcept Therapeutics, Inc. 1,612,555 2,131,920 30,985 Eagle Pharmaceuticals, Inc. 1,612,555 2,131,920 31,999,913 I,861,579 <td< td=""><td>28,000</td><td>ANI Pharmaceuticals, Inc.</td><td>1,630,247</td><td>1,726,760</td></td<>	28,000	ANI Pharmaceuticals, Inc.	1,630,247	1,726,760
48,444 Arena Pharmaceuticals, Inc. 2,224,778 2,200,326 73,000 Arrowhead Pharmaceuticals, Inc. 1,334,061 4,630,390 47,831 Avid Bioservices, Inc. 191,146 366,864 15,000 Biohaven Pharmaceutical Holding Co., Ltd. 657,508 816,600 29,000 Blueprint Medicines Corp. 2,174,620 2,323,190 64,991 Cardiovascular Systems, Inc. 1,852,532 3,157,913 51,000 CareDx, Inc. 1,354,440 1,100,070 357,600 Catalyst Pharmaceuticals, Inc. 1,863,457 1,341,000 95,000 Catasys, Inc. 1,867,035 1,549,450 19,138 Celldex Therapeutics, Inc. 863,139 42,678 148,940 Chimerix, Inc. 800,336 302,348 155,000 Concert Pharmaceuticals, Inc. 1,915,692 1,429,875 325,000 Conformis, Inc. 1,138,618 487,500 129,708 Concert Tharmaceuticals, Inc. 1,915,692 1,429,875 335,000 Energent BioSolutions, Inc. 2,330,032 3,075,150 35,000 Energent BioSolutions, Inc.	506,300	Antares Pharma, Inc.	1,734,827	2,379,610
73,000 Arrowhead Pharmaceuticals, Inc. 1,334,061 4,630,390 47,831 Avid Bioservices, Inc. 191,146 366,864 15,000 Biohaven Pharmaceutical Holding Co., Ltd. 657,508 816,600 29,000 Blueprint Medicines Corp. 2,174,620 2,323,190 64,991 Cardiovascular Systems, Inc. 1,852,532 3,157,913 51,000 CareDX, Inc. 1,354,440 1,1000,703 357,600 Catalyst Pharmaceuticals, Inc. 1,863,457 1,341,000 95,000 Catasys, Inc. 1,867,035 1,549,450 19,138 Celldex Therapeutics, Inc. 863,139 42,678 148,940 Chimerix, Inc. 800,336 302,348 155,000 Concert Pharmaceuticals, Inc. 1,915,692 1,429,875 325,000 Conformis, Inc. 1,138,618 487,500 129,708 Corcept Therapeutics, Inc. 1,138,618 487,500 129,708 Corcept Therapeuticals, Inc. 1,612,555 2,131,920 133,000 Eagle Pharmaceuticals, Inc. 1,612,555 2,131,920 14,600 Deciphera Pharmaceuticals, Inc. <td>174,900</td> <td>Apyx Medical Corp.</td> <td>1,229,550</td> <td>1,479,654</td>	174,900	Apyx Medical Corp.	1,229,550	1,479,654
47,831Avid Bioservices, Inc.191,146366,86415,000Biohaven Pharmaceutical Holding Co., Ltd.657,508816,60029,000Blueprint Medicines Corp.2,174,6202,323,19064,991Cardiovascular Systems, Inc.1,852,5323,157,91351,000CareDx, Inc.1,354,4401,100,070357,600Catalyst Pharmaceuticals, Inc.1,863,4571,341,00095,000Catasys, Inc.1,867,0351,549,45019,138Celldex Therapeutics, Inc.863,13942,678148,940Chimerix, Inc.800,336302,348155,000Concert Pharmaceuticals, Inc.1,915,6921,429,875325,000Conformis, Inc.1,915,6921,429,875325,000Conformis, Inc.1,138,618487,500129,708Corcept Therapeutica, Inc.1,929,9131,569,46716,000Deciphera Pharmaceuticals, Inc.1,929,9131,861,57972,000Editas Medicine, Inc.1,929,9131,861,57972,000Editas Medicine, Inc.1,612,5552,131,92057,000Emergent BioSolutions, Inc.2,330,0323,075,15035,000Enanta Pharmaceuticals, Inc.1,618,4992,162,300210,759Endo International PLC2,979,312988,46073,000Enserion Therapeutics, Inc.2,031,5002,981,50073,000Enserion Therapeutics, Inc.1,675,4051,162,31974,100Enserion Therapeutics, Inc.2,031,5002,981,500 <td< td=""><td>48,444</td><td>Arena Pharmaceuticals, Inc.</td><td>2,224,778</td><td>2,200,326</td></td<>	48,444	Arena Pharmaceuticals, Inc.	2,224,778	2,200,326
15,000 Biohaven Pharmaceutical Holding Co., Ltd. 657,508 816,600 29,000 Blueprint Medicines Corp. 2,174,620 2,323,190 64,991 Cardiovascular Systems, Inc. 1,852,532 3,157,913 51,000 CareDx, Inc. 1,354,440 1,100,070 357,600 Catalyst Pharmaceuticals, Inc. 1,863,457 1,341,000 95,000 Catasys, Inc. 1,867,035 1,549,450 19,138 Celldex Therapeutics, Inc. 863,139 42,678 148,940 Chimerix, Inc. 800,336 302,348 155,000 Cocret Pharmaceuticals, Inc. 1,915,692 1,429,875 325,000 Coformis, Inc. 1,138,618 487,500 129,708 Corcet Therapeutics, Inc. 2,540,013 1,569,467 16,000 Deciphera Pharmaceuticals, Inc. 1,929,913 1,861,579 72,000 Editas Medicine, Inc. 1,612,555 2,131,920 57,000 Emergent BioSolutions, Inc. 2,330,032 3,075,150 35,000 Emergent BioSolutions, Inc. 2,979,312	73,000	Arrowhead Pharmaceuticals, Inc.	1,334,061	4,630,390
29,000Blueprint Medicines Corp.2,174,6202,323,19064,991Cardiovascular Systems, Inc.1,852,5323,157,91351,000Care Dx, Inc.1,354,4401,100,070357,600Catalyst Pharmaceuticals, Inc.1,863,4571,341,00095,000Catasys, Inc.1,867,0351,549,45019,138Celldex Therapeutics, Inc.863,13942,678148,940Chimerix, Inc.800,336302,348155,000Concert Pharmaceuticals, Inc.1,915,6921,429,875325,000Conformis, Inc.1,138,618487,500129,708Corcept Therapeutics, Inc.2,540,0131,569,46716,000Deciphera Pharmaceuticals, Inc.1,929,9131,861,57972,000Editas Medicine, Inc.1,612,5552,131,92057,000Emergent BioSolutions, Inc.2,330,0323,075,15035,000International PLC2,979,312988,46073,000Ensign Group, Inc.2,062,4223,312,01050,000Esperion Therapeutics, Inc.2,031,5002,981,50027,100FibroGen, Inc.1,675,4051,162,319129,700FibroGen, Inc.1,675,4051,162,319129,700FibroGen, Inc.1,675,4051,162,319129,700FibroGen, Inc.1,675,4051,162,319129,700FibroGen, Inc.1,675,4051,162,319129,700FibroGen, Inc.1,675,4051,162,319129,700FibroGen, Inc.1,675,4051,162,319	47,831	Avid Bioservices, Inc.	191,146	366,864
64.991Cardiovascular Systems, Inc.1.852,5323.157,91351,000CareDx, Inc.1.354,4401,100,070357,600Catalyst Pharmaceuticals, Inc.1.863,4571,341,00095,000Catasys, Inc.1.867,0351,549,45019,138Celldex Therapeutics, Inc.863,13942,678148,940Chimerix, Inc.800,336302,348155,000Concert Pharmaceuticals, Inc.1.915,6921,429,875325,000Conformis, Inc.1,138,618487,500129,708Corcept Therapeutics, Inc.2,540,0131,569,46716,000Deciphera Pharmaceuticals, Inc.1,929,9131,861,57972,000Editas Medicine, Inc.1,912,5552,131,92057,000Emergent BioSolutions, Inc.2,330,0323,075,15035,000Enanta Pharmaceuticals, Inc.1,618,4992,162,300210,759Endo International PLC2,979,312988,46073,000Esgerion Therapeutics, Inc.2,031,5002,981,50027,100FibroGen, Inc.1,675,4051,162,319129,700Fludigm Corp.1,795,221451,35652,003Fulgent Genetics, Inc.633,628670,839	15,000	Biohaven Pharmaceutical Holding Co., Ltd.	657,508	816,600
51,000CareDx, Inc.1,354,4401,100,070357,600Catalyst Pharmaceuticals, Inc.1,863,4571,341,00095,000Catasys, Inc.1,867,0351,549,45019,138Celldex Therapeutics, Inc.863,13942,678148,940Chimerix, Inc.800,336302,348155,000Concert Pharmaceuticals, Inc.1,915,6921,429,875325,000Conformis, Inc.1,138,618487,500129,708Corcept Therapeutics, Inc.2,540,0131,569,46716,000Deciphera Pharmaceuticals, Inc.1,919,29131,861,57972,000Editas Medicine, Inc.1,612,5552,131,92057,000Emergent BioSolutions, Inc.2,330,0323,075,15035,000Enanta Pharmaceuticals, Inc.1,618,4992,162,300210,759Endo International PLC2,979,312988,46073,000Esperion Therapeutics, Inc.2,031,5002,981,50050,000Esperion Therapeutics, Inc.1,675,4051,162,319129,700FibroGen, Inc.1,675,4051,162,319129,700FibroGen, Inc.1,675,4051,162,319129,700FibroGen, Inc.1,795,221451,35652,003Fulgent Genetics, Inc.633,628670,839	29,000	Blueprint Medicines Corp.	2,174,620	2,323,190
357,600Catalyst Pharmaceuticals, Inc.1,863,4571,341,00095,000Catasys, Inc.1,867,0351,549,45019,138Celldex Therapeutics, Inc.863,13942,678148,940Chimerix, Inc.800,336302,348155,000Concert Pharmaceuticals, Inc.1,915,6921,429,875325,000Conformis, Inc.1,138,618487,500129,708Corcept Therapeutics, Inc.1,138,618487,500129,708Corcept Therapeutics, Inc.2,540,0131,569,46716,000Deciphera Pharmaceuticals, Inc.1,929,9131,861,57972,000Editas Medicine, Inc.1,612,5552,131,92057,000Emergent BioSolutions, Inc.2,330,0323,075,15035,000Enanta Pharmaceuticals, Inc.1,618,4992,162,300210,759Endo International PLC2,979,312988,46073,000Esperion Therapeutics, Inc.2,062,4223,312,01050,000Esperion Therapeutics, Inc.2,031,5002,981,50027,100FibroGen, Inc.1,675,4051,162,319129,700Fludigm Corp.1,795,221451,35652,003Fulgent Genetics, Inc.633,628670,839	64,991	Cardiovascular Systems, Inc.	1,852,532	3,157,913
95,000Carsy, Inc.1,867,0351,549,45019,138Celldex Therapeutics, Inc.863,13942,678148,940Chimerix, Inc.800,336302,348155,000Concert Pharmaceuticals, Inc.1,915,6921,429,875325,000Conformis, Inc.1,138,618487,500129,708Corcept Therapeutics, Inc.2,540,0131,569,46716,000Deciphera Pharmaceuticals, Inc.411,411995,84030,985Eagle Pharmaceuticals, Inc.1,929,9131,861,57972,000Editas Medicine, Inc.1,612,5552,131,92075,000Emergent BioSolutions, Inc.2,330,0323,075,15035,000Enanta Pharmaceuticals, Inc.1,618,4992,162,300210,759Endo International PLC2,979,312988,46073,000Ensign Group, Inc.2,031,5002,981,50074,100Esperion Therapeutics, Inc.2,031,5002,981,50075,000Ensign Group, Inc.2,031,5002,981,50075,000Esperion Therapeutics, Inc.2,031,5002,981,50075,000Esperion Therapeutics, Inc.2,031,5002,981,50075,000FibroGen, Inc.1,675,4051,162,31971,000FibroGen, Inc.1,795,221451,35675,003Fulgent Goreics, Inc.633,628670,839	51,000	CareDx, Inc.	1,354,440	1,100,070
19,138Cellex Therapeutics, Inc.863,13942,678148,940Chimerix, Inc.800,336302,348155,000Concert Pharmaceuticals, Inc.1,915,6921,429,875325,000Conformis, Inc.1,138,618487,500129,708Corcept Therapeutics, Inc.2,540,0131,569,46716,000Deciphera Pharmaceuticals, Inc.411,411995,84030,985Eagle Pharmaceuticals, Inc.1,929,9131,861,57972,000Editas Medicine, Inc.1,612,5552,131,92057,000Emergent BioSolutions, Inc.2,330,0323,075,15035,000Enanta Pharmaceuticals, Inc.1,618,4992,162,300210,759Endo International PLC2,979,312988,46073,000Esperion Therapeutics, Inc.2,031,5002,981,50050,000Esperion Therapeutics, Inc.1,675,4051,162,319210,759FibroGen, Inc.1,675,4051,162,319129,700Fibrig Corp.1,795,221451,35652,003Fulgent Genetics, Inc.633,628670,839	357,600	Catalyst Pharmaceuticals, Inc.	1,863,457	1,341,000
148,940Chimerix, Inc.800,336302,348155,000Concert Pharmaceuticals, Inc.1,915,6921,429,875325,000Conformis, Inc.1,138,618487,500129,708Corcept Therapeutics, Inc.2,540,0131,569,46716,000Deciphera Pharmaceuticals, Inc.411,411995,84030,985Eagle Pharmaceuticals, Inc.1,929,9131,861,57972,000Editas Medicine, Inc.1,612,5552,131,92057,000Emergent BioSolutions, Inc.2,330,0323,075,15035,000Enanta Pharmaceuticals, Inc.1,618,4992,162,300210,759Endo International PLC2,979,312988,46073,000Esperion Therapeutics, Inc.2,031,5002,981,50050,000Esperion Therapeutics, Inc.1,675,4051,162,319129,700Fludigm Corp.1,675,4051,162,319129,700Fludigm Corp.1,795,221451,35652,003Fulgent Genetics, Inc.633,628670,839	95,000	Catasys, Inc.	1,867,035	1,549,450
155,000Concert Pharmaceuticals, Inc.1,915,6921,429,875325,000Conformis, Inc.1,138,618487,500129,708Corcept Therapeutics, Inc.2,540,0131,569,46716,000Deciphera Pharmaceuticals, Inc.411,411995,84030,985Eagle Pharmaceuticals, Inc.1,929,9131,861,57972,000Editas Medicine, Inc.1,612,5552,131,92057,000Emergent BioSolutions, Inc.2,330,0323,075,15035,000Enanta Pharmaceuticals, Inc.1,618,4992,162,300210,759Endo International PLC2,979,312988,46073,000Esperion Therapeutics, Inc.2,031,5002,981,50057,000Esperion Therapeutics, Inc.2,031,5002,981,50027,100FibroGen, Inc.1,675,4051,162,319129,700Fluidigm Corp.1,795,221451,35652,003Fulgent Genetics, Inc.633,628670,839	19,138	Celldex Therapeutics, Inc.	863,139	42,678
325,000Conformis, Inc.1,138,618487,500129,708Corcept Therapeutics, Inc.2,540,0131,569,46716,000Deciphera Pharmaceuticals, Inc.411,411995,84030,985Eagle Pharmaceuticals, Inc.1,929,9131,861,57972,000Editas Medicine, Inc.1,612,5552,131,92057,000Emergent BioSolutions, Inc.2,330,0323,075,15035,000Enanta Pharmaceuticals, Inc.1,618,4992,162,300210,759Endo International PLC2,979,312988,46073,000Esperion Therapeutics, Inc.2,031,5002,981,50027,100FibroGen, Inc.1,675,4051,162,319129,700Fluidigm Corp.1,795,221451,35652,003Fulgent Genetics, Inc.633,628670,839	148,940	Chimerix, Inc.	800,336	302,348
129,708Corcept Therapeutics, Inc.2,540,0131,569,46716,000Deciphera Pharmaceuticals, Inc.411,411995,84030,985Eagle Pharmaceuticals, Inc.1,929,9131,861,57972,000Editas Medicine, Inc.1,612,5552,131,92057,000Emergent BioSolutions, Inc.2,330,0323,075,15035,000Enanta Pharmaceuticals, Inc.1,618,4992,162,300210,759Endo International PLC2,979,312988,46073,000Esperion Therapeutics, Inc.2,062,4223,312,01050,000Esperion Therapeutics, Inc.2,031,5002,981,50027,100FibroGen, Inc.1,675,4051,162,319129,700Fluidigm Corp.1,795,221451,35652,003Fulgent Genetics, Inc.633,628670,839	155,000	Concert Pharmaceuticals, Inc.	1,915,692	1,429,875
16,000Deciphera Pharmaceuticals, Inc.411,411995,84030,985Eagle Pharmaceuticals, Inc.1,929,9131,861,57972,000Editas Medicine, Inc.1,612,5552,131,92057,000Emergent BioSolutions, Inc.2,330,0323,075,15035,000Enanta Pharmaceuticals, Inc.1,618,4992,162,300210,759Endo International PLC2,979,312988,46073,000Ensign Group, Inc.2,062,4223,312,01050,000Esperion Therapeutics, Inc.2,031,5002,981,50027,100FibroGen, Inc.1,675,4051,162,319129,700Fluidigm Corp.1,795,221451,35652,003Fulgent Genetics, Inc.633,628670,839	325,000	Conformis, Inc.	1,138,618	487,500
30,985Eagle Pharmaceuticals, Inc.1,929,9131,861,57972,000Editas Medicine, Inc.1,612,5552,131,92057,000Emergent BioSolutions, Inc.2,330,0323,075,15035,000Enanta Pharmaceuticals, Inc.1,618,4992,162,300210,759Endo International PLC2,979,312988,46073,000Ensign Group, Inc.2,062,4223,312,01050,000Esperion Therapeutics, Inc.2,031,5002,981,50027,100FibroGen, Inc.1,675,4051,162,319129,700Fluidigm Corp.1,795,221451,35652,003Fulgent Genetics, Inc.633,628670,839	129,708	Corcept Therapeutics, Inc.	2,540,013	1,569,467
72,000Editas Medicine, Inc.1,612,5552,131,92057,000Emergent BioSolutions, Inc.2,330,0323,075,15035,000Enanta Pharmaceuticals, Inc.1,618,4992,162,300210,759Endo International PLC2,979,312988,46073,000Ensign Group, Inc.2,062,4223,312,01050,000Esperion Therapeutics, Inc.2,031,5002,981,50027,100FibroGen, Inc.1,675,4051,162,319129,700Fluidigm Corp.1,795,221451,35652,003Fulgent Genetics, Inc.633,628670,839	16,000	Deciphera Pharmaceuticals, Inc.	411,411	995,840
57,000Emergent BioSolutions, Inc.2,330,0323,075,15035,000Enanta Pharmaceuticals, Inc.1,618,4992,162,300210,759Endo International PLC2,979,312988,46073,000Ensign Group, Inc.2,062,4223,312,01050,000Esperion Therapeutics, Inc.2,031,5002,981,50027,100FibroGen, Inc.1,675,4051,162,319129,700Fluidigm Corp.1,795,221451,35652,003Fulgent Genetics, Inc.633,628670,839	30,985	Eagle Pharmaceuticals, Inc.	1,929,913	1,861,579
35,000Enanta Pharmaceuticals, Inc.1,618,4992,162,300210,759Endo International PLC2,979,312988,46073,000Ensign Group, Inc.2,062,4223,312,01050,000Esperion Therapeutics, Inc.2,031,5002,981,50027,100FibroGen, Inc.1,675,4051,162,319129,700Fluidigm Corp.1,795,221451,35652,003Fulgent Genetics, Inc.633,628670,839	72,000	Editas Medicine, Inc.	1,612,555	2,131,920
210,759Endo International PLC2,979,312988,46073,000Ensign Group, Inc.2,062,4223,312,01050,000Esperion Therapeutics, Inc.2,031,5002,981,50027,100FibroGen, Inc.1,675,4051,162,319129,700Fluidigm Corp.1,795,221451,35652,003Fulgent Genetics, Inc.633,628670,839	57,000	Emergent BioSolutions, Inc.	2,330,032	3,075,150
73,000Ensign Group, Inc.2,062,4223,312,01050,000Esperion Therapeutics, Inc.2,031,5002,981,50027,100FibroGen, Inc.1,675,4051,162,319129,700Fluidigm Corp.1,795,221451,35652,003Fulgent Genetics, Inc.633,628670,839	35,000	Enanta Pharmaceuticals, Inc.	1,618,499	2,162,300
50,000Esperion Therapeutics, Inc.2,031,5002,981,50027,100FibroGen, Inc.1,675,4051,162,319129,700Fluidigm Corp.1,795,221451,35652,003Fulgent Genetics, Inc.633,628670,839	210,759	Endo International PLC	2,979,312	988,460
27,100FibroGen, Inc.1,675,4051,162,319129,700Fluidigm Corp.1,795,221451,35652,003Fulgent Genetics, Inc.633,628670,839	73,000	Ensign Group, Inc.	2,062,422	3,312,010
129,700Fluidigm Corp.1,795,221451,35652,003Fulgent Genetics, Inc.633,628670,839	50,000	Esperion Therapeutics, Inc.	2,031,500	2,981,500
52,003 Fulgent Genetics, Inc. 633,628 670,839	27,100	FibroGen, Inc.	1,675,405	1,162,319
	129,700	Fluidigm Corp.	1,795,221	451,356
220,000 GenMark Diagnostics, Inc. 1,422,300 1,058,200	52,003	Fulgent Genetics, Inc.	633,628	670,839
	220,000	GenMark Diagnostics, Inc.	1,422,300	1,058,200

46,000 Haemonetics Corp. 4,540,419 5,285,44 63,001 Halozyme Therapeutics, Inc. 1,132,325 1,132,91 100,000 Horizon Therapeutics, Inc. 304,898 111,91 116,649 Infnity Pharmaceuticals, Inc. 304,898 111,92 100,425 Innoviva, Inc. 1,420,133 1,422,0 19,000 Ioegen, Inc. 3,901,522 1,298,27 49,645 Insmed, Inc. 1,504,997 1,815,52 24,300 Integer Holdings Corp. 1,716,120 1,954,44 10,000 Integer Holdings Corp. 1,741,615 1,614,00 10,000 Joint Corp. 1,741,615 1,614,00 80,000 Joint Corp. 1,741,615 1,644,00 80,000 Joint Corp. 1,743,853 2,698,267 2,656,99 11,000 Lagnad Pharmaceuticals, Inc. 1,848,708 2,214,11 1,939,241 1,939,241 1,939,241 1,939,241 1,939,241 1,942,94 1,938,243 1,942,94 1,930,93 1,942,94 1,938,243 1,942,94 1,938,243 1,942,94 1,938,3743 829,71 1,9	Number of			
32.300 Globus Medical, Inc. Class A \$ 1,691,834 \$ 1,901,83 46,000 Haemonetics Corp. 4,540,419 5,285,44 63.901 Halozyme Therapeutics, Inc. 1,123,235 1,132,90 100,000 Horizon Therapeutica, Inc. 304,898 111,91 100,425 Innoviva, Inc. 1,420,133 1,422,0 19,000 Inogen, Inc. 3,901,522 1,298,27 49,645 Insmed, Inc. 1,716,120 1,954,4 10,000 Integer Holdings Corp. 1,716,120 1,954,4 10,000 Intersect ENT, Inc. 832,853 1,239,24 46,498 Intersect ENT, Inc. 3,307,316 2,212,97 100,000 Joint Corp. 1,714,161 1,614,00 80,000 Jounce Therapeutics, Inc. 378,639 698,44 1125,544 Lambeus Holdings, Inc. 2,588,267 2,656,96 10,000 Ligand Pharmaceuticals, Inc. 1,433,859 1,042,99 11,000 Livanhous PLC 1,383,743 829,77 29,941 Lambeus Holdings, Inc. 2,588,267 2,656,99 10,000 </th <th>Shares</th> <th></th> <th>Cost</th> <th>Fair Value</th>	Shares		Cost	Fair Value
46,000 Haemonetics Corp. 4,540,419 5,285,44 63,901 Halozyme Therapeutics, Inc. 1,123,235 1,132,91 100,000 Horizon Therapeutics, Inc. 304,898 111,91 116,649 Infinity Pharmaceuticals, Inc. 304,898 111,92 100,425 Innovia, Inc. 1,420,133 1,422,0 19,000 Ioegen, Inc. 3,901,522 1,298,27 49,645 Insmed, Inc. 1,504,997 1,185,55 24,300 Integer Holdings Corp. 1,716,120 1,954,4 10,000 Intercept Pharmaceuticals, Inc. 1,393,241 1,157,80 32,500 IRhythm Technologies, Inc. 3,067,916 2,212,97 100,000 Joint Corp. 1,741,615 1,614,00 80,000 Jounce Therapeutics, Inc. 1,848,708 2,214,17 129,544 Lamtheus Holdings, Inc. 2,598,267 2,666,99 10,000 Ligand Pharmaceuticals, Inc. 1,433,859 1,042,99 11,000 LivaNova PLC 1,383,743 829,77 129,941 Luminex Corp. 620,395 693,44 1		Healthcare (Continued)		
63,901 Halozyme Therapeutics, Inc. 1,123,235 1,132,90 100,000 Horizon Therapeutics PLC 1,395,221 3,620,00 116,649 Infinity Pharmaceuticals, Inc. 304,898 111,90 100,0425 Innovita, Inc. 1,420,133 1,422,0 19,000 Inogen, Inc. 3,901,522 1,298,22 49,645 Inserd, Inc. 1,504,997 1,185,35 24,300 Integer Holdings Corp. 1,516,4997 1,157,80 32,500 iRhythm Technologies, Inc. 3,067,916 2,212,93 10,000 Joune Cherapeutics, Inc. 3,067,916 2,212,93 10,000 Joune Cherapeutics, Inc. 3,067,916 2,212,93 10,000 Joune Cherapeutics, Inc. 3,88,708 2,214,11 129,544 Laminex Holdings, Inc. 2,598,267 2,656,94 10,000 Ligand Pharmaceuticals, Inc. 1,483,743 2,697,01 11,000 Ligand Pharmaceuticals, Inc. 1,483,743 2,697,01 11,000 LivaNova PLC 1,854,015 316,84 <tr< th=""><th>32,300</th><th>Globus Medical, Inc. Class A</th><th>\$ 1,691,834</th><th>\$ 1,901,824</th></tr<>	32,300	Globus Medical, Inc. Class A	\$ 1,691,834	\$ 1,901,824
100,000 Horizon Therapeutics PLC 1,395,221 3,620,00 116,649 Infinity Pharmaceuticals, Inc. 304,898 111,91 100,0425 Innovia, Inc. 3,901,522 1,298,27 49,645 Insmed, Inc. 3,901,522 1,298,27 49,645 Insmed, Inc. 1,504,997 1,855,57 24,300 Interger Holdings Corp. 1,716,120 1.954,44 10,000 Intersect ENT, Inc. 823,853 1,239,221 10,000 Intersect ENT, Inc. 3,067,916 2,212,30 100,000 Joint Corp. 1,741,615 1,614,00 80,000 Jounce Therapeutics, Inc. 2,598,267 2,656,59 100,000 Laind Pharmaceuticals, Inc. 1,433,859 1,042,99 11,000 Ligand Pharmaceuticals, Inc. 1,433,859 1,042,99 11,000 Ligand Pharmaceuticals, Inc. 1,433,859 1,042,99 11,000 Ligand Pharmaceuticals, Inc. 1,433,859 1,042,99 11,000 Lainde Pharmaceuticals, Inc. 2,170,676 3,026,11 <t< td=""><td>46,000</td><td>Haemonetics Corp.</td><td>4,540,419</td><td>5,285,400</td></t<>	46,000	Haemonetics Corp.	4,540,419	5,285,400
116,649 Infinity Pharmaceuticals, Inc. 304,898 111,93 100,425 Innovia, Inc. 1,420,133 1,422,0 19,000 Inogen, Inc. 3,901,522 1,298,27 49,645 Insmed, Inc. 1,504,997 1,185,57 24,300 Integer Holdings Corp. 1,716,120 1,954,44 10,000 Intercept Pharmaceuticals, Inc. 832,853 1,239,24 46,498 Intersect ENT, Inc. 1,303,241 1,157,80 32,500 Rhythm Technologies, Inc. 3,067,916 2,212,97 100,000 Joint Corp. 1,741,615 1,614,00 80,000 Jounce Therapeutics, Inc. 378,639 698,44 115,500 Karyopharm Therapeutics, Inc. 1,848,708 2,214,11 129,541 Lantheus Holdings, Inc. 2,598,267 2,656,99 110,000 Ligand Pharmaceuticals, Inc. 1,484,783 2,687,01 110,000 Ligand Pharmaceuticals, Inc. 2,170,676 3,026,11 128,633 Momenta Pharmaceuticals, Inc. 2,170,676 3,026,11	63,901	Halozyme Therapeutics, Inc.	1,123,235	1,132,965
100,425 Innoviva, Inc. 1,420,133 1,422,03 19,000 Inogen, Inc. 3,901,522 1,298,27 49,645 Insmed, Inc. 1,504,997 1,185,55 24,300 Integer Holdings Corp. 1,716,120 1,954,44 10,000 Intercept Pharmaceuticals, Inc. 1,393,241 1,157,83 32,500 iRhythm Technologies, Inc. 3,067,916 2,212,92 100,000 Jounce Therapeutics, Inc. 3,067,916 2,212,92 100,000 Jounce Therapeutics, Inc. 1,741,615 1,644,00 80,000 Jounce Therapeutics, Inc. 1,848,708 2,214,11 129,544 Lantheus Holdings, Inc. 2,598,267 2,656,94 10,000 Ligand Pharmaceuticals, Inc. 1,433,859 1,042,94 11,000 Liyanova PLC 1,383,743 829,73 29,941 Luminex Corp. 620,335 693,44 90,793 Mallinckrodt PLC 1,854,015 316,88 17,000 Masimo Corp. 1,487,853 2,687,02 36,600 <	100,000	Horizon Therapeutics PLC	1,395,221	3,620,000
19,000 Inogen, Inc. 3,901,522 1,298,22 49,645 Insmed, Inc. 1,504,997 1,185,52 24,300 Integer Holdings Corp. 1,716,120 1,954,44 10,000 Intersect PNT Inc. 832,853 1,239,241 33,2500 iRbythm Technologies, Inc. 3,067,916 2,212,93 100,000 Joint Corp. 1,741,615 1,614,00 80,000 Jource Therapeutics, Inc. 3,78,639 698,44 115,500 Karyopharm Therapeutics, Inc. 1,848,708 2,214,11 129,544 Lamtneus Holdings, Inc. 2,598,267 2,656,99 10,000 Ligand Pharmaceuticals, Inc. 1,383,743 829,77 29,941 Luminex Corp. 620,395 693,43 90,793 Mallinckrodt PLC 1,884,763 2,687,09 128,633 Momenta Pharmaceuticals, Inc. 2,170,676 3,026,14 128,634 Momenta Pharmaceuticals, Inc. 2,170,676 3,026,14 128,633 Momenta Pharmaceuticals, Inc. 2,297,14 2,537,92 61,806 Natus Medical, Inc. 2,297,14 2,538,89	116,649	Infinity Pharmaceuticals, Inc.	304,898	111,983
49,645 Insmed, Inc. 1,504,997 1,185,52 24,300 Integer Holdings Corp. 1,716,120 1,954,44 100.00 Interget Pharmaceuticals, Inc. 832,853 1,239,24 46,498 Intersect ENT, Inc. 1,393,241 1,157,84 32,500 iRhythm Technologies, Inc. 3,067,916 2,212,92 100,000 Joint Corp. 1,741,615 1,614,00 80,000 Jounce Therapeutics, Inc. 378,639 698,44 115,500 Karyopharm Therapeutics, Inc. 1,848,708 2,214,12 129,544 Lantheus Holdings, Inc. 2,598,267 2,656,92 10,000 Ligand Pharmaceuticals, Inc. 1,383,743 829,77 21,941 Luminex Corp. 620,395 693,44 90,793 Mallinckrodt PLC 1,884,015 316,88 17,000 Masimo Corp. 1,487,853 2,687,01 36,000 Medpace Holdings, Inc. 2,297,141 2,537,92 61,806 Natus Medical, Inc. 2,297,141 2,537,92 61,800 Neore Corp. 1,690,693 1,311,77 21,600	100,425	Innoviva, Inc.	1,420,133	1,422,018
24,300 Integer Holdings Corp. 1,716,120 1,954,4 10,000 Intercept Pharmaceuticals, Inc. 832,853 1,239,24 46,498 Intersect ENT, Inc. 1,393,241 1,157,86 32,500 iRhythm Technologies, Inc. 3,067,916 2,212,92 100,000 Joint Corp. 1,741,615 1,614,00 80,000 Jounce Therapeutics, Inc. 1,848,708 2,214,11 129,544 Lantheus Holdings, Inc. 2,598,267 2,656,94 10,000 Ligand Pharmaceuticals, Inc. 1,433,859 1,042,94 11,000 LivaNova PLC 1,383,743 829,77 29,941 Luminex Corp. 620,395 693,44 90,793 Mallinckrodt PLC 1,854,015 316,88 11,000 Masimo Corp. 1,471,615 3,026,10 128,633 Momenta Pharmaceuticals, Inc. 2,170,676 3,026,10 128,633 Momenta Pharmaceuticals, Inc. 2,259,917 2,038,99 20,100 Nedgae Holdings, Inc. 2,259,917 2,038,99 21,140 Network Medical, Inc. 2,259,917 2,038,93 <tr< td=""><td>19,000</td><td>Inogen, Inc.</td><td>3,901,522</td><td>1,298,270</td></tr<>	19,000	Inogen, Inc.	3,901,522	1,298,270
10.000 Intercept Pharmaceuticals, Inc. 832,853 1,239,24 46,498 Intersect ENT, Inc. 1,393,241 1,157,80 32,500 iRhythm Technologies, Inc. 3,067,916 2,212,90 100,000 Joint Corp. 1,741,615 1,614,00 80,000 Jounce Therapeutics, Inc. 378,639 698,44 115,500 Karyopharm Therapeutics, Inc. 1,848,708 2,214,11 129,544 Lantheus Holdings, Inc. 2,598,267 2,656,94 10,000 Ligand Pharmaceuticals, Inc. 1,433,859 1,042,94 11,000 Ligand Pharmaceuticals, Inc. 1,383,743 829,77 29,941 Luminex Corp. 620,395 693,44 90,793 Mallinckrodt PLC 1,884,015 316,80 17,000 Masimo Corp. 1,487,853 2,687,03 36,000 Medpace Holdings, Inc. 2,297,141 2,537,92 61,806 Natus Medical, Inc. 2,299,11 2,038,94 20,100 Neogen Corp. 1,690,693 1,11,77 21,600	49,645	Insmed, Inc.	1,504,997	1,185,523
46,498 Intersect ENT, Inc. 1,393,241 1,157,80 32,500 iRhythm Technologies, Inc. 3,067,916 2,212,92 100,000 Joint Corp. 1,741,615 1,614,00 80,000 Jounce Therapeutics, Inc. 378,639 698,44 115,500 Karyopharm Therapeutics, Inc. 378,639 698,44 1129,544 Lantheus Holdings, Inc. 2,598,267 2,656,92 10,000 Ligand Pharmaceuticals, Inc. 1,433,859 1,042,94 11,000 LivaNova PLC 1,883,743 829,77 29,941 Luminex Corp. 620,395 693,44 90,793 Mallinckrodt PLC 1,854,015 316,86 17,000 Masimo Corp. 1,487,853 2,687,02 36,000 Medpace Holdings, Inc. 2,297,141 2,537,92 20,100 Neogen Corp. 1,690,693 1,311,71 21,600 Nety Medical, Inc. 2,297,141 2,538,92 20,100 Neogen Corp. 1,600,693 1,311,71 21,600 Nevor Corp. 1,301,876 2,538,88 92,114 NewLink Genetics Cor	24,300	Integer Holdings Corp.	1,716,120	1,954,449
32,500 iRhythm Technologies, Inc. 3,067,916 2,212,92 100,000 Joint Corp. 1,741,615 1,614,00 80,000 Jounce Therapeutics, Inc. 378,639 698,44 115,500 Karyopharm Therapeutics, Inc. 1,848,708 2,214,12 129,544 Lantheus Holdings, Inc. 2,598,267 2,656,94 10,000 Ligand Pharmaceuticals, Inc. 1,433,859 1,042,94 11,000 LivaNova PLC 1,383,743 829,77 29,941 Luminex Corp. 620,395 693,44 90,793 Mallinckrodt PLC 1,854,015 316,85 17,000 Masimo Corp. 1,487,853 2,687,00 36,000 Medpace Holdings, Inc. 2,170,676 3026,14 128,633 Momenta Pharmaceuticals, Inc. 2,297,141 2,537,92 61,806 Natus Medical, Inc. 2,259,917 2,038,92 20,100 Neogen Corp. 1,690,693 1,311,72 21,600 Newo Corp. 1,301,876 2,338,84 92,114 NewLink Genetics Corp. 960,996 233,00 43,000 N	10,000	Intercept Pharmaceuticals, Inc.	832,853	1,239,200
100,000 Joint Corp. 1,741,615 1,614,00 80,000 Jounce Therapeutics, Inc. 378,639 698,44 115,500 Karyopharm Therapeutics, Inc. 1,848,708 2,214,11 129,544 Lantheus Holdings, Inc. 2,598,267 2,656,9- 10,000 Ligand Pharmaceuticals, Inc. 1,433,859 1,042,90 11,000 LivaNova PLC 1,383,743 829,77 29,941 Luminex Corp. 620,395 693,44 90,793 Mallinckrodt PLC 1,854,015 316,80 17,000 Masimo Corp. 1,487,853 2,687,00 36,000 Medpace Holdings, Inc. 2,170,676 3,026,14 128,633 Momenta Pharmaceuticals, Inc. 2,297,141 2,537,99 61,806 Natus Medical, Inc. 2,259,917 2,038,90 20,100 Neogen Corp. 1,690,693 1,311,77 21,600 Nevoro Corp. 1,301,876 2,538,80 92,114 NewLink Genetics Corp. 960,996 233,00 43,000 Novocure Ltd. 2,029,424 3,623,6 31,979 Orthofix Med	46,498	Intersect ENT, Inc.	1,393,241	1,157,800
80.00 Joune Therapeutics, Inc. 378,639 698,44 115,500 Karyopharm Therapeutics, Inc. 1,848,708 2,214,11 129,544 Lantheus Holdings, Inc. 2,598,267 2,656,94 10,000 Ligand Pharmaceuticals, Inc. 1,433,859 1,042,90 11,000 LivaNova PLC 1,383,743 829,72 29,941 Luminex Corp. 620,395 693,43 90,793 Mallinckrodt PLC 1,854,015 316,86 17,000 Masimo Corp. 1,487,853 2,687,02 36,000 Medpace Holdings, Inc. 2,170,676 3,026,11 128,633 Momenta Pharmaceuticals, Inc. 2,297,141 2,537,92 61,806 Natus Medical, Inc. 2,297,141 2,537,93 20,100 Neogen Corp. 1,609,693 1,311,77 21,600 Newro Corp. 1,609,969 233,00 43,000 Novocure Ltd. 2,029,424 3,623,66 31,979 Orthofix Medical, Inc. 1,628,261 1,476,75 36,500 The Pennant Grou	32,500	iRhythm Technologies, Inc.	3,067,916	2,212,925
115,500 Karyopharn Therapeutics, Inc. 1,848,708 2,214,11 129,544 Lantheus Holdings, Inc. 2,598,267 2,656,94 10,000 Ligand Pharmaceuticals, Inc. 1,433,859 1,042,90 11,000 LivaNova PLC 1,383,743 829,72 29,941 Luminex Corp. 620,395 693,43 90,793 Mallinckrodt PLC 1,854,015 316,80 17,000 Masimo Corp. 1,487,853 2,687,02 36,000 Medpace Holdings, Inc. 2,170,676 3,026,11 128,633 Momenta Pharmaceuticals, Inc. 2,297,141 2,537,92 61,806 Natus Medical, Inc. 2,259,917 2,038,93 20,100 Neogen Corp. 1,690,693 1,311,72 21,600 Nevo Corp. 1,690,693 1,311,72 21,600 Nevo Corp. 1,301,876 2,538,80 92,114 NeuLink Genetics Corp. 960,996 233,00 43,000 Novocure Ltd. 2,029,424 3,623,66 31,979 Orthofix Medical, Inc. 1,628,261 1,476,77 54,500 The Pennant Gr	100,000	Joint Corp.	1,741,615	1,614,000
129,544 Lautheus Holdings, Inc. 2,598,267 2,656,94 10,000 Ligand Pharmaceuticals, Inc. 1,433,859 1,042,94 11,000 LivaNova PLC 1,383,743 829,77 29,941 Luminex Corp. 620,395 693,44 90,793 Mallinckrodt PLC 1,854,015 316,88 17,000 Masimo Corp. 1,487,853 2,687,03 36,000 Medpace Holdings, Inc. 2,170,676 3,026,10 128,633 Momenta Pharmaceuticals, Inc. 2,297,141 2,537,93 61,806 Natus Medical, Inc. 2,259,917 2,038,93 20,100 Neogen Corp. 1,690,693 1,311,77 21,600 Nevro Corp. 1,301,876 2,538,80 92,114 NewLink Genetics Corp. 960,996 233,00 43,000 Novocure Ltd. 2,029,424 3,623,6 31,979 Orthofix Medical, Inc. 1,628,261 1,476,79 54,762 Pacira BioSciences, Inc. 2,136,584 2,480,7 36,500 The Pennant Group, Inc. - 1,207,02 53,500 Phibro Animal He	80,000	Jounce Therapeutics, Inc.	378,639	698,400
10,000 Ligand Pharmaceuticals, Inc. 1,433,859 1,042,90 11,000 LivaNova PLC 1,383,743 829,72 29,941 Luminex Corp. 620,395 693,43 90,793 Mallinckrodt PLC 1,854,015 316,80 17,000 Masimo Corp. 1,487,853 2,687,03 36,000 Medpace Holdings, Inc. 2,170,676 3,026,10 128,633 Momenta Pharmaceuticals, Inc. 2,297,141 2,537,93 61,806 Natus Medical, Inc. 2,259,917 2,038,93 20,100 Neogen Corp. 1,690,693 1,311,77 21,600 Newro Corp. 1,301,876 2,538,80 92,114 NewLink Genetics Corp. 960,996 233,00 43,000 Novocure Ltd. 2,029,424 3,623,6 31,979 Orthofix Medical, Inc. 1,628,261 1,476,79 54,762 Pacira BioSciences, Inc. 2,136,584 2,480,7 36,500 The Pennant Group, Inc. - 1,207,02 53,500 Phibro Animal Health Corp. Class A 1,763,131 1,328,44 44,000 PTC Th	115,500	Karyopharm Therapeutics, Inc.	1,848,708	2,214,135
11,000LivaNova PLC1,383,743829,7229,941Luminex Corp.620,395693,4290,793Mallinckrodt PLC1,854,015316,8417,000Masimo Corp.1,487,8532,687,0236,000Medpace Holdings, Inc.2,170,6763,026,14128,633Momenta Pharmaceuticals, Inc.2,297,1412,537,9261,806Natus Medical, Inc.2,259,9172,038,9220,100Neogen Corp.1,690,6931,311,7221,600Nevro Corp.1,301,8762,538,8092,114NewLink Genetics Corp.960,996233,0443,000Novocure Ltd.2,029,4243,623,6331,979Orthofix Medical, Inc.1,207,023,83,14354,762Pacira BioSciences, Inc.2,136,5842,480,755,500The Pennant Group, Inc1,207,0253,500Phibro Animal Health Corp. Class A1,763,1311,328,4444,000PTC Therapeutics, Inc.888,7472,113,3244,500Puma Biotechnology, Inc.2,140,222389,323,746Reata Pharmaceuticals, Inc. Class A698,347765,79	129,544	Lantheus Holdings, Inc.	2,598,267	2,656,947
29,941Luminex Corp.620,395693,4390,793Mallinckrodt PLC1,854,015316,8017,000Masimo Corp.1,487,8532,687,0336,000Medpace Holdings, Inc.2,170,6763,026,10128,633Momenta Pharmaceuticals, Inc.2,297,1412,537,9261,806Natus Medical, Inc.2,259,9172,038,9320,100Neogen Corp.1,690,6931,311,7221,600Nevro Corp.1,301,8762,538,8092,114NewLink Genetics Corp.960,996233,0043,000Novocure Ltd.2,029,4243,623,6631,979Orthofix Medical, Inc.1,628,2611,476,7954,762Pacira BioSciences, Inc.2,136,5842,480,753,500Phibro Animal Health Corp. Class A1,763,1311,328,4444,000PTC Therapeutics, Inc.888,7472,113,3344,500Puma Biotechnology, Inc.2,140,222389,373,746Reata Pharmaceuticals, Inc. Class A698,347765,79	10,000	Ligand Pharmaceuticals, Inc.	1,433,859	1,042,900
90,793Mallinckrodt PLC1,854,015316,8417,000Masimo Corp.1,487,8532,687,0336,000Medpace Holdings, Inc.2,170,6763,026,14128,633Momenta Pharmaceuticals, Inc.2,297,1412,537,9361,806Natus Medical, Inc.2,259,9172,038,9320,100Neogen Corp.1,690,6931,311,7721,600Nevro Corp.1,301,8762,538,8692,114NewLink Genetics Corp.960,996233,0443,000Novocure Ltd.2,029,4243,623,6531,979Orthofix Medical, Inc.1,628,2611,476,7954,762Pacira BioSciences, Inc.2,136,5842,480,753,500Phibro Animal Health Corp. Class A1,763,1311,328,4444,000PTC Therapeutics, Inc.888,7472,113,3344,500Puma Biotechnology, Inc.2,140,222389,373,746Reata Pharmaceuticals, Inc. Class A698,347765,79	11,000	LivaNova PLC	1,383,743	829,730
17,000Masimo Corp.1,487,8532,687,0236,000Medpace Holdings, Inc.2,170,6763,026,14128,633Momenta Pharmaceuticals, Inc.2,297,1412,537,9261,806Natus Medical, Inc.2,259,9172,038,9320,100Neogen Corp.1,690,6931,311,7221,600Newro Corp.1,301,8762,538,8492,114NewLink Genetics Corp.960,996233,0443,000Novocure Ltd.2,029,4243,623,6531,979Orthofix Medical, Inc.1,628,2611,476,7954,762Pacira BioSciences, Inc.2,136,5842,480,753,500Phibro Animal Health Corp. Class A1,763,1311,328,4444,000PTC Therapeutics, Inc.888,7472,113,3344,500Puma Biotechnology, Inc.2,140,222389,373,746Reata Pharmaceuticals, Inc. Class A698,347765,79	29,941	Luminex Corp.	620,395	693,433
36,000Medpace Holdings, Inc.2,170,6763,026,10128,633Momenta Pharmaceuticals, Inc.2,297,1412,537,9261,806Natus Medical, Inc.2,259,9172,038,9220,100Neogen Corp.1,690,6931,311,7221,600Nevro Corp.1,301,8762,538,8092,114NewLink Genetics Corp.960,996233,0092,114NewLink Genetics Corp.960,996233,0043,000Novocure Ltd.2,029,4243,623,6031,979Orthofix Medical, Inc.1,628,2611,476,7954,762Pacira BioSciences, Inc.2,136,5842,480,753,500Phibro Animal Health Corp. Class A1,763,1311,328,4444,000PTC Therapeutics, Inc.888,7472,113,3244,500Puma Biotechnology, Inc.2,140,222389,373,746Reata Pharmaceuticals, Inc. Class A698,347765,79	90,793	Mallinckrodt PLC	1,854,015	316,867
128,633Momenta Pharmaceuticals, Inc.2,297,1412,537,9261,806Natus Medical, Inc.2,259,9172,038,9220,100Neogen Corp.1,690,6931,311,7221,600Nevro Corp.1,301,8762,538,8092,114NewLink Genetics Corp.960,996233,0043,000Novocure Ltd.2,029,4243,623,6031,979Orthofix Medical, Inc.1,628,2611,476,7954,762Pacira BioSciences, Inc.2,136,5842,480,736,500The Pennant Group, Inc.1,207,001,328,4044,000PTC Therapeutics, Inc.888,7472,113,3244,500Puma Biotechnology, Inc.2,140,222389,373,746Reata Pharmaceuticals, Inc. Class A698,347765,79	17,000	Masimo Corp.	1,487,853	2,687,020
61,806Natus Medical, Inc.2,259,9172,038,9220,100Neogen Corp.1,690,6931,311,7721,600Nevro Corp.1,301,8762,538,8092,114NewLink Genetics Corp.960,996233,0443,000Novocure Ltd.2,029,4243,623,6631,979Orthofix Medical, Inc.1,628,2611,476,7954,762Pacira BioSciences, Inc.2,136,5842,480,736,500The Pennant Group, Inc1,207,0353,500Phibro Animal Health Corp. Class A1,763,1311,328,4044,000PTC Therapeutics, Inc.888,7472,113,3344,500Puma Biotechnology, Inc.2,140,222389,373,746Reata Pharmaceuticals, Inc. Class A698,347765,79	36,000	Medpace Holdings, Inc.	2,170,676	3,026,160
20,100Neogen Corp.1,690,6931,311,7221,600Nevro Corp.1,301,8762,538,8692,114NewLink Genetics Corp.960,996233,0043,000Novocure Ltd.2,029,4243,623,6631,979Orthofix Medical, Inc.1,628,2611,476,7954,762Pacira BioSciences, Inc.2,136,5842,480,736,500The Pennant Group, Inc1,207,0053,500Phibro Animal Health Corp. Class A1,763,1311,328,4444,000PTC Therapeutics, Inc.888,7472,113,3244,500Puma Biotechnology, Inc.2,140,222389,373,746Reata Pharmaceuticals, Inc. Class A698,347765,79	128,633	Momenta Pharmaceuticals, Inc.	2,297,141	2,537,929
21,600New Corp.1,301,8762,538,8092,114NewLink Genetics Corp.960,996233,0043,000Novocure Ltd.2,029,4243,623,6031,979Orthofix Medical, Inc.1,628,2611,476,7954,762Pacira BioSciences, Inc.2,136,5842,480,736,500The Pennant Group, Inc1,207,0953,500Phibro Animal Health Corp. Class A1,763,1311,328,4044,000PTC Therapeutics, Inc.888,7472,113,3344,500Puma Biotechnology, Inc.2,140,222389,373,746Reata Pharmaceuticals, Inc. Class A698,347765,79	61,806	Natus Medical, Inc.	2,259,917	2,038,980
92,114NewLink Genetics Corp.960,996233,0443,000Novocure Ltd.2,029,4243,623,631,979Orthofix Medical, Inc.1,628,2611,476,7954,762Pacira BioSciences, Inc.2,136,5842,480,736,500The Pennant Group, Inc1,207,0353,500Phibro Animal Health Corp. Class A1,763,1311,328,4044,000PTC Therapeutics, Inc.888,7472,113,3344,500Puma Biotechnology, Inc.2,140,222389,333,746Reata Pharmaceuticals, Inc. Class A698,347765,79	20,100	Neogen Corp.	1,690,693	1,311,726
43,000Novocure Ltd.2,029,4243,623,631,979Orthofix Medical, Inc.1,628,2611,476,7954,762Pacira BioSciences, Inc.2,136,5842,480,736,500The Pennant Group, Inc1,207,0253,500Phibro Animal Health Corp. Class A1,763,1311,328,4444,000PTC Therapeutics, Inc.888,7472,113,3244,500Puma Biotechnology, Inc.2,140,222389,373,746Reata Pharmaceuticals, Inc. Class A698,347765,79	21,600	Nevro Corp.	1,301,876	2,538,864
31,979 Orthofix Medical, Inc. 1,628,261 1,476,79 54,762 Pacira BioSciences, Inc. 2,136,584 2,480,7 36,500 The Pennant Group, Inc. - 1,207,09 53,500 Phibro Animal Health Corp. Class A 1,763,131 1,328,40 44,000 PTC Therapeutics, Inc. 888,747 2,113,33 44,500 Puma Biotechnology, Inc. 2,140,222 389,37 3,746 Reata Pharmaceuticals, Inc. Class A 698,347 765,79	92,114	NewLink Genetics Corp.	960,996	233,048
54,762 Pacira BioSciences, Inc. 2,136,584 2,480,7 36,500 The Pennant Group, Inc. - 1,207,02 53,500 Phibro Animal Health Corp. Class A 1,763,131 1,328,44 44,000 PTC Therapeutics, Inc. 888,747 2,113,32 44,500 Puma Biotechnology, Inc. 2,140,222 389,37 3,746 Reata Pharmaceuticals, Inc. Class A 698,347 765,79	43,000	Novocure Ltd.	2,029,424	3,623,610
36,500 The Pennant Group, Inc. - 1,207,03 53,500 Phibro Animal Health Corp. Class A 1,763,131 1,328,40 44,000 PTC Therapeutics, Inc. 888,747 2,113,33 44,500 Puma Biotechnology, Inc. 2,140,222 389,33 3,746 Reata Pharmaceuticals, Inc. Class A 698,347 765,79	31,979	Orthofix Medical, Inc.	1,628,261	1,476,790
53,500Phibro Animal Health Corp. Class A1,763,1311,328,4044,000PTC Therapeutics, Inc.888,7472,113,3244,500Puma Biotechnology, Inc.2,140,222389,323,746Reata Pharmaceuticals, Inc. Class A698,347765,79	54,762	Pacira BioSciences, Inc.	2,136,584	2,480,719
44,000PTC Therapeutics, Inc.888,7472,113,3244,500Puma Biotechnology, Inc.2,140,222389,323,746Reata Pharmaceuticals, Inc. Class A698,347765,79	36,500	The Pennant Group, Inc.	-	1,207,055
44,500 Puma Biotechnology, Inc. 2,140,222 389,37 3,746 Reata Pharmaceuticals, Inc. Class A 698,347 765,79	53,500	Phibro Animal Health Corp. Class A	1,763,131	1,328,405
3,746Reata Pharmaceuticals, Inc. Class A698,347765,79	44,000	PTC Therapeutics, Inc.	888,747	2,113,320
	44,500	Puma Biotechnology, Inc.	2,140,222	389,375
	3,746	Reata Pharmaceuticals, Inc. Class A	698,347	765,795
32,000 REGENXBIO, Inc. 2,194,706 1,311,04	32,000	REGENXBIO, Inc.	2,194,706	1,311,040

Shares			Cost	Fair Value
	Healthcare (Continued)			
46.022		¢	1 212 422	ф <u>дс1 с</u> 4
	Revance Therapeutics, Inc.	\$	1,313,422	\$ 761,54
97,381	Sangamo Therapeutics, Inc.		1,572,024	815,07
28,000	,		1,276,770	1,130,64
200,000			3,074,161	728,00
	STAAR Surgical Co.		2,621,319	2,314,18
17,958	Supernus Pharmaceuticals, Inc.		734,482	425,96
40,500	,		2,350,835	1,677,91
	Syneos Health, Inc.		1,772,939	2,022,15
-	Tactile Systems Technology, Inc.		988,924	1,215,18
	Trevena, Inc.		383,012	97,94
84,088	Triple-S Management Corp. Class B		1,870,992	1,554,78
10,000	Turning Point Therapeutics, Inc.		435,030	622,90
	Ultragenyx Pharmaceutical, Inc.		745,597	512,52
118,000	Vanda Pharmaceuticals, Inc.		2,061,896	1,936,38
89,300	Veracyte, Inc.		2,156,520	2,493,25
56,400	Voyager Therapeutics, Inc.		1,245,423	786,78
	Total Healthcare	18.15%	143,974,720	140,357,42
	Industrials			
32,800	AAR Corp.		1,197,575	1,479,28
110,500	Advanced Drainage Systems, Inc.		2,840,319	4,291,82
190,000	American Superconductor Corp.			
			1,622,950	1,491,50
89,000	Apogee Enterprises, Inc.		1,622,950 3,542,876	1,491,50 2,892,50
	Apogee Enterprises, Inc. Argan, Inc.			
	Argan, Inc.		3,542,876	2,892,50
47,187	Argan, Inc. Astec Industries, Inc.		3,542,876 3,216,125	2,892,50 1,894,08
47,187 31,000 67,000	Argan, Inc. Astec Industries, Inc.		3,542,876 3,216,125 1,104,411	2,892,50 1,894,08 1,302,00
47,187 31,000 67,000 17,000	Argan, Inc. Astec Industries, Inc. Atlas Air Worldwide Holdings, Inc.		3,542,876 3,216,125 1,104,411 3,355,021	2,892,50 1,894,08 1,302,00 1,847,19
47,187 31,000 67,000 17,000 27,972	Argan, Inc. Astec Industries, Inc. Atlas Air Worldwide Holdings, Inc. AZZ, Inc. Barrett Business Services, Inc.		3,542,876 3,216,125 1,104,411 3,355,021 761,090	2,892,50 1,894,08 1,302,00 1,847,19 781,15
47,187 31,000 67,000 17,000 27,972 77,900	Argan, Inc. Astec Industries, Inc. Atlas Air Worldwide Holdings, Inc. AZZ, Inc. Barrett Business Services, Inc. Beacon Roofing Supply, Inc.		3,542,876 3,216,125 1,104,411 3,355,021 761,090 1,701,358	2,892,50 1,894,08 1,302,00 1,847,19 781,15 2,530,34
47,187 31,000 67,000 17,000 27,972 77,900 126,000	Argan, Inc. Astec Industries, Inc. Atlas Air Worldwide Holdings, Inc. AZZ, Inc. Barrett Business Services, Inc. Beacon Roofing Supply, Inc. BMC Stock Holdings, Inc.		3,542,876 3,216,125 1,104,411 3,355,021 761,090 1,701,358 2,365,044 2,054,908	2,892,50 1,894,08 1,302,00 1,847,19 781,15 2,530,34 2,491,24 3,614,94
47,187 31,000 67,000 17,000 27,972 77,900 126,000 235,226	Argan, Inc. Astec Industries, Inc. Atlas Air Worldwide Holdings, Inc. AZZ, Inc. Barrett Business Services, Inc. Beacon Roofing Supply, Inc.		3,542,876 3,216,125 1,104,411 3,355,021 761,090 1,701,358 2,365,044	2,892,50 1,894,08 1,302,00 1,847,19 781,15 2,530,34 2,491,24
47,187 31,000 67,000 17,000 27,972 77,900 126,000 235,226 153,067	Argan, Inc. Astec Industries, Inc. Atlas Air Worldwide Holdings, Inc. AZZ, Inc. Barrett Business Services, Inc. Beacon Roofing Supply, Inc. BMC Stock Holdings, Inc. Briggs & Stratton Corp.		3,542,876 3,216,125 1,104,411 3,355,021 761,090 1,701,358 2,365,044 2,054,908 3,072,271	2,892,50 1,894,08 1,302,00 1,847,19 781,15 2,530,34 2,491,24 3,614,94 1,566,60 3,889,43
47,187 31,000 67,000 17,000 27,972 77,900 126,000 235,226 153,067 88,000	Argan, Inc. Astec Industries, Inc. Atlas Air Worldwide Holdings, Inc. AZZ, Inc. Barrett Business Services, Inc. Beacon Roofing Supply, Inc. BMC Stock Holdings, Inc. Briggs & Stratton Corp. Builders FirstSource, Inc.		3,542,876 3,216,125 1,104,411 3,355,021 761,090 1,701,358 2,365,044 2,054,908 3,072,271 2,774,168	2,892,50 1,894,08 1,302,00 1,847,19 781,15 2,530,34 2,491,24 3,614,94 1,566,60

Number of Shares		Cost	I	Fair Value
	Industrials (Continued)			
9,700	EMCOR Group, Inc.	\$ 663,737	\$	837,110
	Exponent, Inc.	1,535,204		1,518,220
	Fluor Corp.	1,538,386		1,542,496
	FTI Consulting, Inc.	3,071,863		3,054,216
49,800	Granite Construction, Inc.	2,186,321		1,377,966
	Great Lakes Dredge & Dock Corp.	882,507		1,036,695
67,300	Greenbrier Cos., Inc.	1,972,863		2,182,539
31,000	H&E Equipment Services, Inc.	1,224,541		1,036,330
95,000	Hawaiian Holdings, Inc.	3,200,961		2,782,550
58,600	Heidrick & Struggles International, Inc.	1,831,463		1,904,500
70,000	Herc Holdings, Inc.	3,249,632		3,425,800
85,007	Herman Miller, Inc.	2,976,423		3,540,542
97,236	Hillenbrand, Inc.	3,035,289		3,238,931
110,000	HNI Corp.	4,052,736		4,120,600
36,800	Hyster-Yale Materials Handling, Inc.	1,694,170		2,169,728
52,500	Insperity, Inc.	2,289,540		4,517,100
60,200	Insteel Industries, Inc.	1,210,152		1,293,698
72,900	Kforce, Inc.	2,672,173		2,894,130
34,000	Korn Ferry	1,497,025		1,441,600
150,000	Manitowoc Co., Inc.	5,024,298		2,625,000
52,000	Masonite International Corp.	3,219,378		3,754,920
20,600	McGrath RentCorp	1,556,551		1,576,724
100,000	Meritor, Inc.	2,307,050		2,619,000
140,400	MRC Global, Inc.	2,067,640		1,915,056
34,833	MYR Group, Inc.	1,029,960		1,135,207
50,000	NN, Inc.	403,458		462,500
161,000	NOW, Inc.	1,976,524		1,809,640
28,919	Orion Group Holdings, Inc.	195,782		150,090
100,000	Patrick Industries, Inc.	4,497,380		5,243,000
119,800	Primoris Services Corp.	2,986,328		2,664,352
13,600	SkyWest, Inc.	793,875		878,968
247,570	Steelcase, Inc. Class A	3,858,327		5,065,282
50,000	Systemax, Inc.	1,044,886		1,258,000
72,500	Terex Corp.	2,057,231		2,159,050
55,600	Titan Machinery, Inc.	952,958		821,768

Schedule of Investments (Continued) QS U.S. Small Capitalization Equity CIF (Continued) December 31, 2019

Number of				
Shares			Cost	Fair Value
	Industrials (Continued)			
46,700	Triton International Ltd.	\$	1,468,907	\$ 1,877,340
74,399	TrueBlue, Inc.		1,721,518	1,790,040
97,100	Veritiv Corp.		2,687,817	1,909,957
114,403	Werner Enterprises, Inc.		4,086,531	4,163,125
33,500	WESCO International, Inc.		1,645,385	1,989,565
	Total Industrials	16.38%	124,166,033	126,660,028
	Information Technology			
122,000	ADTRAN, Inc.		2,631,543	1,206,580
31,000	Alarm.com Holdings, Inc.		2,015,483	1,332,070
216,524	Amkor Technology, Inc.		2,242,248	2,814,812
152,631	Benchmark Electronics, Inc.		5,143,657	5,244,401
27,000	Benefitfocus, Inc.		1,129,991	592,380
231,840	Box, Inc. Class A		4,348,018	3,890,275
82,992	Ciena Corp.		1,872,300	3,542,928
78,000	Cirrus Logic, Inc.		4,051,592	6,427,980
69,100	CommVault Systems, Inc.		4,153,666	3,084,624
48,000	Cornerstone OnDemand, Inc.		2,677,368	2,810,400
25,000	Diodes, Inc.		778,828	1,409,250
55,000	Domo, Inc. Class B		2,212,744	1,194,600
35,000	DSP Group, Inc.		489,976	550,900
84,483	Etsy, Inc.		1,387,530	3,742,597
69,192	EVERTEC, Inc.		1,140,682	2,355,296
47,400	Fabrinet		2,521,709	3,073,416
6,000	Fair Isaac Corp.		834,731	2,248,080
25,000	Five9, Inc.		1,326,457	1,639,500
14,000	HubSpot, Inc.		2,136,422	2,219,000
47,627	Intevac, Inc.		430,841	336,247
201,261	Lattice Semiconductor Corp.		1,327,943	3,852,135
44,605	Manhattan Associates, Inc.		1,827,849	3,557,249
81,436	Methode Electronics, Inc.		3,451,751	3,204,506
275,000	MobileIron, Inc.		1,608,682	1,336,500
48,765	NETGEAR, Inc.		2,375,461	1,195,230
63,000	NetScout Systems, Inc.		1,728,333	1,516,410

_

umber of Shares			Cost	Fair Value
	Information Technology (Continued)			
125 205		¢	2 222 257	¢ 2.021.92
	NIC, Inc.	\$		\$ 3,021,832
53,116	Onto Innovation, Inc.		1,700,063	1,940,85
29,341	Paylocity Holding Corp.		2,479,384	3,544,98
	Plexus Corp.		1,641,454	2,308,20
45,000	Progress Software Corp.		1,645,252	1,869,75
31,300	Qualys, Inc.		2,594,521	2,609,48
96,391	Rubicon Project, Inc.		389,495	786,55
65,000	SailPoint Technologies Holding, Inc.		2,075,387	1,534,00
110,000	Sanmina Corp.		4,002,138	3,766,40
26,966	ScanSource, Inc.		1,194,119	996,39
66,000	SPS Commerce, Inc.		2,968,684	3,657,72
14,617	Tech Data Corp.		1,285,945	2,099,00
76,000	Tenable Holdings, Inc.		2,431,631	1,820,96
10,737	Trade Desk, Inc. Class A		1,686,931	2,789,25
40,000	Verint Systems, Inc.		1,664,358	2,214,40
54,000	Workiva, Inc.		2,921,884	2,270,70
159,200	Xperi Corp.		3,801,622	2,945,20
103,000	Yelp, Inc.		4,316,552	3,587,49
	Total Information Technology	13.99%	96,977,481	108,140,54
	Materials			
103,000	Boise Cascade Co.		3,303,632	3,762,59
212,169	Coeur Mining, Inc.		2,048,772	1,714,32
57,037	Greif, Inc. Class A		3,389,333	2,521,03
120,000	Louisiana-Pacific Corp.		3,525,050	3,560,40
111,700	O-I Glass, Inc.		1,178,256	1,332,58
64,000	PolyOne Corp.		1,814,816	2,354,56
180,000	Rayonier Advanced Materials, Inc.		2,341,522	691,20
50,000	Schnitzer Steel Industries, Inc. Class A		1,190,722	1,084,00
71,815	Schulman A, Inc.		31,096	
275,200	SunCoke Energy, Inc.		2,287,774	1,714,49
73,000	Trinseo S.A.		4,488,623	2,716,33
200,000	Tronox Holdings PLC Class A		3,293,252	2,284,00
185,000	Verso Corp. Class A		4,796,906	3,335,55
107,000	Warrior Met Coal, Inc.		2,575,219	2,260,91
	Total Materials	3.80%	36,264,973	29,331,97

Shares			Cost	Fair Value
	Real Estate			
365,759	DiamondRock Hospitality Co. REIT	\$	3,939,920	\$ 4,052,61
642	Forestar Group, Inc.		8,382	13,38
137,000	GEO Group, Inc. REIT		3,496,867	2,275,57
138,529	Hersha Hospitality Trust REIT		2,679,060	2,015,59
53,208	Marcus & Millichap, Inc.		1,468,866	1,981,99
107,702	Pebblebrook Hotel Trust REIT		3,754,959	2,887,49
52,900	RE/MAX Holdings, Inc. Class A		2,369,219	2,036,12
221,300	Realogy Holdings Corp.		2,069,387	2,142,18
235,000	RLJ Lodging Trust REIT		5,154,498	4,164,20
99,351	RPT Realty REIT		1,332,023	1,494,23
37,618	Ryman Hospitality Properties, Inc. REIT		2,314,113	3,259,97
136,000	Sabra Health Care REIT, Inc. REIT		2,594,518	2,902,24
184,131	Summit Hotel Properties, Inc. REIT		2,880,995	2,272,17
292,861	Sunstone Hotel Investors, Inc. REIT		4,575,905	4,076,62
	Total Real Estate	4.60%	38,638,712	35,574,41
	Telecommunication Services			
70,000	Cogent Communications Holdings, Inc.		3,384,776	4,606,70
389,598	Glu Mobile, Inc.		3,373,556	2,357,06
33,000	Intelsat S.A.		1,067,966	231,99
52,300	Marcus Corp.		2,052,208	1,661,57
49,300	Telephone & Data Systems, Inc.		1,607,668	1,253,69
	Total Telecommunication Services	1.31%	11,486,174	10,111,02
	Utilities			
80,000	Avista Corp.		3,261,800	3,847,20
36,445	IDACORP, Inc.		3,455,836	3,892,32
30,500	National Fuel Gas Co.		1,654,222	1,419,47
60,000	New Jersey Resources Corp.		2,950,145	2,674,20
45,156	ONE Gas, Inc.		3,293,089	4,225,24
64 000	Otter Tail Corp.		3,195,081	3,282,56
64,000	oner fan corp.		- , ,	- , - ,

Schedule of Investments (Continued) QS U.S. Small Capitalization Equity CIF (Continued) December 31, 2019

Shares			Cost	Fair Value
	Utilities (Continued)			
61,412 Portland Gener	al Electric Co.		\$ 2,833,749	\$ 3,426,175
26,000 Spire, Inc.			1,945,936	2,166,06
	Total Utilities	3.75%	25,763,521	28,990,03
	Total Common Stocks	99.74%	748,234,135	771,194,61
	Total Investments	100.00%	\$ 750,248,825	\$ 773,209,30

CVR - Contingent Value Rights

REIT - Real Estate Investment Trust

Statement of Operations – Selected Fund

Year Ended December 31, 2019

	QS U.S. Small Capitalization Equity CIF
Income	
Interest	\$ 177,979
Dividends (net of foreign withholding taxes of \$11,806)	12,776,058
Total income	12,954,037
Expenses	
Trustee and administrative	411,082
Class R2 expenses	318,352
Class R4 expenses	3,235,153
Total expenses	3,964,587
Net Investment Income	8,989,450
Net Realized Losses on Investments and Futures Contracts	
Net realized losses on investments	(13,491,718)
Net realized losses on futures contracts	(117,747)
Net realized losses	(13,609,465)
Change in Net Unrealized Appreciation	
Investments	140,146,804
Change in net unrealized appreciation	140,146,804
Net realized and unrealized gains on investments and futures contracts	126,537,339
Net Increase in Net Assets Resulting From Operations	\$ 135,526,789

Statement of Changes in Net Assets – Selected Fund Year Ended December 31, 2019

	Ca	S U.S. Small apitalization Equity CIF
Operations		
Net investment income	\$	8,989,450
Net realized losses		(13,609,465)
Change in net unrealized appreciation		140,146,804
Net increase in net assets from operations		135,526,789
Net Decrease in Net Assets From Participant Unit Transactions		(28,209,242)
Increase in Net Assets		107,317,547
Net Assets		
Beginning of year		666,533,756
End of year	\$	773,851,303

Note 1: Nature of Operations and Summary of Significant Accounting Policies

Nature of Operations

Hand Composite Employee Benefit Trust ("HB&T" or "the Trust") was created in order to provide broad and uniform diversification programs for pension and profit sharing plans which, having complied with the requirements of the Internal Revenue Code (the IRC), are exempt from taxation under the provisions of the IRC. The Trust is comprised of 76 portfolios (the Funds); the financial statements of one of those funds, the QS U.S. Small Capitalization Equity CIF (the Fund), are included in this report.

Each class of the Fund has equal rights as to earnings and assets except that each class bears different distribution, shareholder servicing and transfer agent expenses. Income, expenses (other than expenses attributable to a specific class), and realized and unrealized gains or losses on investments and foreign currency are allocated to each class of units based on its relative net assets.

Class R-INT had an inception date of February 28, 2019.

Class R2 liquidated during 2019.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of investment income and expenses during the reporting period. Actual results could differ from those estimates.

Investment Valuation

All investments in securities are recorded at their estimated fair value. Transfers in and out of Level 1 (quoted market prices), Level 2 (significant other observable inputs) and Level 3 (significant unobservable inputs) are recognized on the period ending date.

Investment Transactions

Investment transactions are accounted for on trade date. Realized gains and losses from investment transactions and unrealized appreciation or depreciation of investments are reported on the identified cost basis.

Futures Contracts

The Fund uses futures contracts generally to gain exposure to, or hedge against, changes in interest rates or gain exposure to, or hedge against, changes in certain asset classes. A futures contract represents a commitment for the future purchase or sale of an asset at a specified price on a specified date.

Upon entering into a futures contract, the Fund is required to deposit cash or cash equivalents with a broker in an amount equal to a certain percentage of the contract amount. This is known as the "initial margin" and subsequent payments ("variation margin") are made or received by the Fund each day, depending on the daily fluctuation in the value of the contract. For certain futures, including foreign denominated futures, variation margin is not settled daily, but is recorded as a net variation margin payable or receivable. Futures contracts are valued daily at the settlement price established by the board of trade or exchange on which they are traded. The daily changes in contract value are recorded as unrealized gains or losses in the statement of operations and the Fund recognizes a realized gain or loss when the contract is closed.

Futures contracts involve, to varying degrees, risk of loss in excess of the amounts reflected in the financial statements. In addition, there is the risk that the Fund may not be able to enter into a closing transaction because of an illiquid secondary market.

Investment Income and Distribution of Income

Dividend income less foreign taxes withheld, if any, is recorded on the ex-dividend date and interest income is recorded on the accrual basis. Investment income is allocated ratably on the valuation dates among all participants. No distributions are made to participants in the Fund until units owned are redeemed, at which time the market value of redeemed units is distributed. Investment income and realized gains (if any) earned by the Fund are reinvested, thereby increasing the respective unit values.

Valuation of Participants' Interest

Units of participation may be purchased or redeemed on the valuation dates at the fair value per unit on such valuation dates. The Fund is valued daily.

Federal Income Taxes

The Fund complies with the requirements under Section 501(a) of the IRC and apportion all of its taxable income to its participants. Therefore, no federal income tax provision is required.

Subsequent Events

As a result of the spread of the COVID-19 coronavirus in 2020, economic uncertainties have arisen which may negatively affect the financial position, results of operations and cash flows of the Fund. The duration of these uncertainties and the ultimate financial effects cannot be reasonably estimated at this time.

Subsequent events have been evaluated through May 22, 2020, which is the date the financial statements were available to be issued.

Investment Management Advisors

The investment management advisor for the Fund is QS Investors, LLC.

Note 2: Investment Advisory Fees and Other Transactions With Affiliates

The Fund is charged a fee by HB&T for trustee/administrative services and other fees which include fund accounting services, transfer agency services, custody services, etc. The Fund has also entered into investment advisory and service agreements with a third party advisor. These fees compensate the advisor for the services it provides and for expenses borne by the advisor under the agreement.

The following table indicates the fees charged to the Fund and the various classes of units within the Fund (as a percentage of net assets). These charges are calculated using the Fund's prior day's total net assets:

Fund	Trustee/ Administrative Fees	Investment Management Fees	Other Fees	Total Fees
QS U.S. Small Capitalization Equity CIF:				
Class R4 Class R - INT	0.03% 0.04%	0.43% 0.00%	0.02% 0.02%	0.48% 0.06%

Notes to Financial Statements

December 31, 2019

Note 3: Financial Highlights

	QS U.S. Small Capitalization Equity CIF				
	CI	Class R4		s R-INT ⁽¹⁾	
Net asset value, beginning of period	\$	8.68	\$	10.16	
Net investment income Net realized and unrealized gains		0.11 1.67		0.13 0.21	
Net increase from investment operations		1.78		0.34	
Net asset value, end of period	\$	10.46	\$	10.50	
Total return		20.51%		3.35%	
Ratio to average net assets:					
Net investment income		1.14%		1.63% (2)	
Expenses		0.48%		0.05% ⁽²⁾	
Expenses with reimbursement		0.75% ⁽²⁾		0.48%	

(1) For the period February 28, 2019 (inception date) to December 31, 2019 (2) Annualized

Note 4: Participant Unit Transactions

	QS U.S. Small Capitalization Equity CI				
	Units	Dollars			
Class R2 ⁽¹⁾ :					
Cost of units redeemed	(5,079,856)	\$ (51,052,555)			
Net change in Class R2 from participant transactions	(5,079,856)	(51,052,555)			
Class R4:					
Proceeds from sales of units	18,160,052	178,125,954			
Cost of units redeemed	(15,908,860)	(155,613,888)			
Net change in Class R4 from participant transactions	2,251,192	22,512,066			
Class R-INT ⁽²⁾ :					
Proceeds from sales of units	36,317	363,535			
Cost of units redeemed	(3,238)	(32,288)			
Net change in Class R-INT from participant transactions	33,079	331,247			
Net decrease in net assets from participant unit transactions		\$ (28,209,242)			

⁽¹⁾ Liquidated during 2019

⁽²⁾ For the period February 28, 2019 (inception date) to December 31, 2019

Note 5: Disclosures About Fair Value of Financial Instruments

Fair value is the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. Fair value measurements must maximize the use of observable inputs and minimize the use of unobservable inputs. There is a hierarchy of three levels of inputs that may be used to measure fair value:

- **Level 1:** Quoted prices in active markets for identical assets or liabilities that the Fund can access at the measurement date.
- Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
- **Level 3:** Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Following is a description of the valuation methodologies and inputs used for assets measured at fair value on a recurring basis and recognized in the accompanying statement of assets and liabilities, as well as the general classification of such assets pursuant to the valuation hierarchy. There have been no significant changes in the valuation techniques during the period ended December 31, 2019.

Short Term Investments. Short term investments, including money market funds, for which market quotations are readily available, are valued at the last reported sales price or official closing price as reported by an independent pricing service on the primary market or exchange on which they are traded and are categorized as Level 1 in the hierarchy.

Common Stocks. Securities traded on a national securities exchange (or reported on the NASDAQ national market) are valued at the last reported sales price or official closing price as reported by an independent pricing service on the primary market or exchange on which they are traded and are categorized as Level 1 in the hierarchy. Certain foreign securities may be fair valued using a pricing service that considers the correlation of the trading patterns of the foreign security to the intraday trading in the U.S. markets for investments, such as American Depository Receipts and the movement of certain indexes of securities based on a statistical analysis of the historical relationship and are categorized as either Level 1 or 2 of the hierarchy.

The following table presents the fair value measurements of assets recognized in the accompanying statement of assets and liabilities measured at fair value on a recurring basis and the level within the fair value hierarchy in which the fair value measurements fall at December 31, 2019.

Notes to Financial Statements

December 31, 2019

	Fair Value Measurements Using							
		Fair Value		uoted Prices in Active Markets for Identical Assets (Level 1)	l Prices ctive Sig ets for d tical Obs sets I		Significa	
QS U.S. Small Capitalization Equity CIF								
Financial Instruments - Assets:								
Short Term Investment	\$	2,014,690	\$	2,014,690	\$	-	\$	-
Common Stocks		771,194,611		771,194,611		-		-
Total Financial Instruments - Assets	\$	773,209,301	\$	773,209,301	\$	0	\$	0

Note 6: Risk Factors

Investment Securities Risk

The Fund invests in various investment securities. Investment securities are exposed to various risks such as interest rate, market and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such change could materially affect the amounts reported in the accompanying statement of assets and liabilities.

Supplemental Information

Schedule of Investment Purchases and Sales – Selected Fund QS U.S. Small Capitalization Equity CIF Year Ended December 31, 2019

Purchases			
Investment Class	Cost		
Common Stocks	\$ 468,798,004		
	Sales		
Investment Class	Proceeds	Cost	Loss
Common Stocks	\$ 470,341,338	\$ 483,833,056	\$ (13,491,718)